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ABSTRACT
NOVEL ANALYTICAL METHODS COMBINING NON-DENATURING CHROMATOGRAPHY
AND MASS SPECTROMETRY TO STUDY BIOPOLYMER STRUCTURE AND INTERACTIONS

MAY 2016

KHAJA MUNEERUDDIN, B. Pharm., JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST

Directed by: Professor Igor A. Kaltashov

Biotherapeutics, an emerging class of medicines containing biopolymers (e.g.,
proteins, peptide, and polysaccharides) have been developed for a variety of indications
including cancer, autoimmune, genetic, and blood diseases. Among these biopolymers
protein therapeutics have been the rapidly growing segment in the pharmaceutical
industry. This trend combined with the complexity of proteins has necessitated the
development of powerful and robust analytical methods to study their structure and
interactions with physiological partners.
Mass spectrometry (MS) has become an indispensable tool to analyze various
attributes of protein drugs such as profiling of intact mass, amino acid sequencing, and
post translational modifications (PTMs). In this work novel analytical methods have
been developed by combining non-denaturing chromatographic separations (such as

vii

size exclusion chromatography and ion exchange chromatography) with native ESI MS.
In addition to providing information of mass and non-covalent assemblies, native ESI MS
has an advantage of probing conformational integrity of proteins by analyzing ionic
charge state distributions in the mass spectrum.
Size exclusion chromatography with online native ESI MS detection method
developed in this work allowed characterization of higher order structure of proteins
and probe aggregation propensity. Using the same SEC/native ESI MS workflow a
method to find kinetics and equilibrium binding constant of transient protein
interactions have also been developed. Combination of ion exchange chromatography
(IXC) with native ESI MS and MS/MS detection was developed and shown to be effective
in characterization of positional isomers of protein conjugates and PTMs of a
biotherapeutic recombinant human interferon beta 1a. To characterize highly
heterogeneous PEGylated glycoprotein (conjugated with a 20kDa PEG) analytical
methods using IXC/native ESI MS combined with limited charge reduction and collisional
activation were developed.
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CHAPTER 1
INTRODUCTION
1.1.

Biopolymers as pharmaceuticals
Biotherapeutics, also known as biologics are a class of medicines containing

biopolymers (e.g., proteins, peptides, polysaccharides, and nucleic acids) either
extracted from biological sources or derived by recombinant DNA technology.1-4 Among
the many biopolymers, protein based therapeutics represent the majority of
biotherapeutics, and in the past few years has seen a rapid growth with now over 212
products approved for the treatment of a variety of chronic and life-threatening
disorders ranging from cancer, metabolic, autoimmune to genetic diseases.5, 6 The main
advantage of biotherapeutics over small molecule drugs is their ability to bind their
physiological target in vivo with high specificity resulting in high potency with fewer side
effects.1 However, owing to large size and complexity of biotherapeutics compared to
small molecule drugs; biotherapeutics tend to be highly heterogeneous due to various
modifications that can happen during expression or upon storage or stress. These
modifications inevitably affect the activity and safety profile of biotherapeutics thus
validating the need of strong and robust analytical methods to characterize them.
1.1.1. Protein based therapeutics
Protein therapeutics constitute a broad type of biological products, which
include recombinant enzymes, monoclonal antibodies, hormones, growth factors, fusion
proteins, cytokines, and blood factors.1 This class of therapeutics usually works by
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controlling immune system, decreasing the inflammatory response, or modulating
various metabolic processes.
To enhance the existing pharmacokinetic profile of protein therapeutics and to
expand the therapeutic activity many strategies have been incorporated resulting in the
development of the so-called second generation protein therapeutics. The notable
strategies among these are genetically engineering the glycosylation pattern7 or fusing
proteins with Fc region of antibody to increase serum half-life8, covalent surface
attachment of polyethylene glycols (PEG) to decrease renal clearance,9 and chemical
modification of protein with drug payload for site specific activity.10
1.1.2. Peptide based therapeutics
Peptide therapeutics are relatively smaller molecules containing fewer than 50
amino acids.

Generally peptide molecules act selectively on various cell surface

receptors such as G protein-coupled receptors.11 Though many peptide drugs have been
approved, the development of peptide therapeutic is more often hindered due to poor
chemical and physical stability, and lack of adequate plasma half-life.2 To overcome
these limitations various chemical strategies such as incorporating specific amino acids,
introducing salt bridges or disulfide bonds to increase solubility and stability are being
researched.12, 13
1.1.3. Polysaccharide based therapeutics (heparin based medicines)
Heparin is a negatively charge linear polysaccharide belonging to the family of
molecules known as glycosaminoglycans.14 Due to involvement of heparin in modulating
proteins of coagulation cascade, heparin has been used as an anticoagulant since 1935
2

for renal dialysis and cardiac surgery. Currently heparin is obtained from porcine
mucosa. Owing to safer and effective profile of bovine heparin, it is being re-evaluated
to be introduced in market.15
1.2.

Structural attributes and heterogeneity of polypeptide based drugs

1.2.1. Sequence variants
Sequence variants of polypeptide based drugs (protein and peptide therapeutics)
refer to unintentional addition or substitution of amino acids during bio-manufacturing
step. This heterogeneity at the primary structure level could be due to DNA mutations,
misincorporation of amino acids during translation step, and mis-cleavage during posttranslational processing.16,

17

It is important to analyze the presence of sequence

variants as it can have an overall effect on specificity, stability, and immunogenicity of
polypeptide drugs.18 In case the amino acid occurs in the functional domain, any
variation of this amino acid can also have an impact on the functional activity.
1.2.2. Enzymatic and non-enzymatic post translational modifications
Post translational modifications (PTMs) add to heterogeneity of primary
structure by enzyme mediated covalent attachment of chemical groups to specific
amino acids (the so-called enzymatic PTMs). Around 300 of these PTMs have been
discovered,

some

which

include

phosphorylation,

glycosylation,

acetylation,

methylation, and ubiquitination. These PTMs play an important role in modulating
localization, stability, and interaction of proteins. For example it is known that
phosphorylation of proteins affects their role in cell cycle, growth, apoptosis and signal
transduction pathways. From the context of protein therapeutics glycosylation;
3

attachment of carbohydrates N-linked to asparagine or O-linked to serine/threonine
residues have been shown and indeed used to enhance their stability.19
PTMs (e.g., deamidation, oxidation, glycation) can also have adverse effects on
proteins and peptides.20, 21 These types of modifications are known as non-enzymatic
PTMs, which occur post-production as a result of storage or stress.
1.2.3. Higher order structure
Correct folding of the polypeptide chain into secondary (alpha helix and beta
sheets) and tertiary structures give rise to a unique three dimensional conformation of
proteins. This higher order structure is not only important for the functional activity, but
also for the stability of protein therapeutics. Unfolding or partial destabilization of the
protein conformation (due to storage, stress or non-enzymatic PTMs) can make them
prone to aggregation, which has an adverse effect on the safety profile of protein drugs
by eliciting immunogenic response in patients. In the case of multimeric proteins,
quaternary structures produced by association with identical monomeric units (homooligomerization) or with non-identical units (hetero-oligomerization) play a role in
function, localization, and stability of protein in vivo by protecting it from proteolytic
degradation.22
1.2.4. Second-generation protein therapeutics
The extent of heterogeneity is enhanced in the second-generation protein
therapeutics especially for products formed by chemical conjugation of drugs (protein –
drug conjugates) or PEG chains on proteins post expression. Although the conjugation
procedure is optimized carefully; it is very difficult to control the occurrence of
4

structural heterogeneity (e.g., number of drug molecules attached or presence of
isomers due to modification at chemically similar sites), and maintain higher order
structure. These heterogeneities affect the properties of such protein therapeutics, and
also present great difficulty in their analytical characterization.
1.2.5. Protein-protein interactions
Protein-protein interactions (PPI) can be classified based on various factos.23
Homo- or hetero-oligomers if interaction occurs between identical or non-identical
protein chains. PPI can be distinguished if the complex formed is obligate or nonobilgate. An obligated complex is formed between two proteins that cannot exist as
stable structures on their own in vivo, and a non-obligate complex is formed between
independently stable proteins. PPI can also be grouped based on binding affinity into
permanent and transient interactions. Understanding protein-protein interactions is
crucial as they are involved with wide range of biological processes including cell-cell
interactions, metabolic, and developmental control. It also plays a key role in drug
development.
Traditionally in drug development strong interactions with the equilibrium
dissociation constant (KD) of low nM were favored (e.g., to develop drug molecules
binding irreversibly with the target enzyme for complete inhibition). Recently, there has
been a shift towards exploiting lower affinity interactions (the so-called transient
protein interactions) with KD in high nM – low µM range, due to their significance in
cellular functions24 and also for the development of targeted drug delivery systems.25
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1.3.

Structural attributes and heterogeneity of polysaccharides (heparin-based
medicines)
Heparin is a mixture of linear polysaccharide chains with molecular weight

ranging from 5000 – 25000 Da. It contains repeating disaccharide units of N-acetyl Dglucosamine and D-glucuronic acid. The heterogeneity of heparin polysaccharide chain
is increased by the presence of a mixture of unsubstituted forms and variable nontemplate driven sulfated forms (N-and O- sulfation of glucosamine and O-sulfation of
glucuronic acid).26 This heterogeneity has made analytical characterization of this class
of medicine very challenging.27 The structural complexity of heparin-based medicines is
reduced in low molecular weight heparins (LMWHs), which are produced from chemical
or enzymatic depolymerization of unfractionated heparin. These LMWHs (e.g., tinzaprin,
dalteparin, enoxaparin) have a mean molecular weight of 5000 Da and have been
demonstrated to have similar anticoagulant activity as heparin.28 Arixtra is a chemically
synthesized anticoagulant containing a fixed length pentasaccharide.
1.4.

Commonly used analytical methods to characterize structural heterogeneity

1.4.1. Liquid chromatography methods
Liquid chromatography (LC) is the first line of methods to characterize structural
heterogeneity of protein therapeutics by separating protein species using different LC
modes. The most common LC techniques for analytical characterization are reverse
phase liquid chromatography, size exclusion chromatography, and ion exchange
chromatography.
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Reverse phase liquid chromatography
Separation in reverse phase liquid chromatography (RPLC) occurs due to
interaction of analytes with bonded ligands of the stationary phase.29 Analytes are
eluted in the increasing order of their hydrophobicity using organic solvent gradient.
This type of chromatography provides excellent resolution and reproducibility, and is
the most common technique used in combination with mass spectrometry detection
due to ease of evaporation of the volatile solvent used for elution. RPLC/MS is an
excellent choice for characterization of peptides; however for proteins its use is limited
to intact mass analysis and to analyze reduced fragments of antibody. Due to the nature
of eluent it cannot be used to analyze intact higher order structure of proteins.
Size exclusion chromatography
Size exclusion chromatography (SEC) is the most common technique used in
biotechnology industry to analyze the presence of higher molecular weight species or
aggregates in protein therapeutics. SEC separates proteins based on their hydrodynamic
radius as they diffuse through porous particles of the stationary phase.30 Isocratic
elution conditions (ionic strength: 100 - 150 mM) using physiological buffers in SEC
separation maintains higher order structure of proteins, which allows it to analyze noncovalent protein interactions. Though SEC is advantageous due to its simplicity and ease
of use, certain limitations do exist such as non-ideality of separation due to interaction
with stationary phase and inaccuracy of molecular weight determination from
calibration curve due to non-globular shape of certain proteins.
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Ion exchange chromatography
Ion exchange chromatography (IXC) is another separation technique in which
protein is in its intact state due to non-denaturing conditions employed for separation.
IXC works by electrostatic interaction of charged groups on the proteins with the ionic
groups of the IXC resin. The pH of the eluent is decided based on the isoelectric point
(pI) of protein being analyzed and mode of ion exchange chromatography: for cation
exchange chromatography pH of eluent is lower than pI such that acidic groups of cation
exchange resin can interact with net positively charged proteins and vice versa for anion
exchange chromatography.31 Elution is carried out using linear salt or pH gradient. Ion
exchange chromatography is extremely powerful for characterization of charge
heterogeneity of proteins.
1.4.2. Mass spectrometry
Since the advent of soft ionization techniques, electrospray ionization (ESI) and
matrix assisted laser desorption ionization (MALDI), mass spectrometry based
techniques have developed at a very fast pace compared to any other analytical
technique. Mass spectrometry has now become a powerful and robust tool for
characterization of various aspects of proteins including intact mass, amino acid
sequencing, PTM profiling, non-covalent complexes, aggregation propensity, and
conformational integrity.32, 33
In a typical ESI MS experiments proteins are buffer exchanged into a solution
containing 1:1 mixture of water and organic solvent. Under these conditions proteins
are unfolded and the multiply charged gas phase ions generated by ESI can be used to
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measure mass accurately. High throughput hyphenated techniques (RPLC/MS or
RPLC/MS/MS) are now being routinely used for detection of intact mass and peptide
sequencing. Intact mass analysis with high accuracy allows identification of proteins and
the presence of any modification. Peptide sequencing of proteins is carried out by using
either bottom-up or top-down approach. In classical bottom-up method protein is
digested using a protease, and the proteolytic peptides generated are analyzed by
LC/MS or tandem MS/MS. In top-down method protein digestion step is completely
eliminated, and the ions for sequencing are produced by fragmenting the intact multiply
charged protein ions in gas phase. Both of these techniques (bottom-up and top-down
MS) have been successfully applied for sequencing, localization and quantitation of
PTMs in protein therapeutics.
Native electrospray mass spectrometry (ESI MS)
Unlike classical scheme native ESI MS can analyze native-like quaternary protein
structure and non-covalent protein/receptor complexes by using near native solvents
such as ammonium acetate.34 It has been an emerging technique and has been recently
shown to characterize protein assemblies extending to sub-million daltons.35
In addition to profiling mass, native ESI MS can also be used to probe large-scale
conformational changes in protein by monitoring ionic charge state distribution in mass
spectrum. Native proteins are compactly folded and therefore gas phase ions generated
by ESI carry relatively fewer charges and show a narrow ionic distribution at high m/z
region. However, unlike folded species ions generated from unfolded protein carry a
larger number of charges and populate at lower m/z region with a broad ionic charge
9

state distribution.36 A bimodal ionic distribution will be detected under conditions when
both compact state (highly structured native-like) and non-native states are present in
equilibrium.
Hydrogen deuterium exchange mass spectrometry
Hydrogen deuterium exchange mass spectrometry (HDX) is a labelling technique
for characterization of structure, dynamics, and the presence of multiple protein
conformers in solution. This technique works by monitoring the exchange of backbone
amide hydrogen with deuterium when exposed to deuterated water (D2O).37 Amide
hydrogens of unstructured regions will show a rapid exchange compared to structured
region, which are protected from HDX resulting in slow exchange. Mass shifts from this
deuterium labelling can be easily measured using MS-based peptide mapping. HDX
experiments have been used for mapping epitopes in antigen-antibody interactions,38 to
map protein-receptor interactions,32,

39

and to compare batch-to-batch variation in

protein therapeutics.40
1.4.3. Light scattering based methods
Dynamic light scattering (DLS)41 and multiangle laser light scattering (MALLS)42
are the two light scattering techniques used for detection of higher molecular weight
species/aggregates in protein therapeutics. Hydrodynamic radius is obtained from DLS,
which is directly correlated with the measured diffusion coefficient.
MALLS determines weight-average molecular weight (Mw) and radius of gyration
(Rg) of proteins from the angular dependence of scattered light. This technique is used
over static light scattering, when Rg is larger than angle of incident light. A typical MALLS
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instrument consists of multiple detectors placed around the flow cell at different angles
with respect to incident beam. Rayleigh ratio (Rθ) measured from the scattered light
intensity at different scattering angles (θ) can be used to extrapolate Mw and Rg using
Zimm’s equation. MALLS is usually used in combination with SEC separation, and can
detect protein aggregates even at very low concentration.43
1.4.4. Circular dichroism
Circular dichroism (CD) spectroscopy of proteins is based on differential
absorption of left- and right- polarized light in 190 – 350 nm range, which is based on
structural asymmetry. CD measurements in far UV region 190 – 250 nm are used for
analysis of secondary structure of proteins, and measurements in near UV region 250 –
300 nm gives information about arrangement of the aromatic side chains and/or
disulfide bridges within the protein. CD experiments are simple to perform, but give low
resolution information.44
1.4.5. Field flow fractionation

Field flow fractionation (FFF) is a separation based technology with application in
characterization of protein aggregates (0.01 - 50µm in size). In this method an external
field applied perpendicular to the channel flow control retention of analytes, and
separation occurs based on diffusion coefficients.45 Smaller molecules elute earlier than
larger molecules. This technique is advantageous as analysis can be carried out directly
in the formulation buffer, but the complexity of instrumentation and data handling have
limited the widespread use of this technique.
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1.5. Commonly used methods to analyze protein interactions
1.5.1. Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) is a label free, solution based method to
get equilibrium dissociation constant (KD), stoichiometry, enthalpy, entropy, and Gibbs
free energy of protein interactions.46 It is based on measurement of heat evolved or
absorbed upon complex formation, when ligand is titrated gradually. Slope and
inflection point of the binding isotherm obtained from ITC can be used to derive KD and
stoichiometry. Even though interactions with KD values of 10-9 to 10-6 M can usually be
analyzed using ITC experiments, concentration of the protein concentration used in
titration needs to be optimized to get the sigmoidal curve. For low affinity interactions
high concentration of proteins needed for ITC can lead to aggregation. Another
limitation of ITC is that it not a high throughput technique.
1.5.2. Surface plasmon resonance
Surface plasmon resonance (SPR) is a widely used technique for qualitative and
quantitative characterization of protein interactions.47 In this technique one of the
binding partners is immobilized on the sensor and the binding information is obtained
by changes in the refractive index of the solvent near the sensor surface upon
association or dissociation of protein complexes. SPR is advantageous as it requires
lesser amount of proteins than ITC to measure interactions in the similar KD range.
However, immobilization of protein can lead to structural changes ultimately affecting
binding data.
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1.5.3. Analytical ultra centrifugation
Analytical ultra centrifugation (AUC) is a powerful technique to characterize
protein solution structure and to determine binding constants of protein association.48 It
is based on real-time measurement of sedimentation of protein under centrifugal force
along the radial position using either absorbance or interference optical systems. AUC
experiments are operated either in sedimentation velocity (higher centrifugal field and
completes in 1-2 hours) or sedimentation equilibrium mode (lower centrifugal field and
takes 12 – 24 hours to complete). It can be used to derive molecular weight, oligomeric
state, presence of aggregates, and equilibrium dissociation constant for protein
association. Equilibrium dissociation constants in the range of 10-4 – 10-8 M can be
detected using AUC; however aggregation of sample at higher concentration and loss of
sample from sticking to sample chamber has to be carefully monitored. AUC data
analysis for single species is straight forward, but complex data handling tools are
required to analyze multi component species.45
1.5.4. Hummel-Dreyer method
Hummel Dreyer method is commonly used to study protein/small ligand binding,
but can also be used for protein/protein interactions. In this method protein is dissolved
in the buffer solution containing the same concentration of ligand used for equilibrating
the SEC column. If there is binding between the protein and ligand a trough will be
detected, and using the area of this trough unbound ligand concentration can be
obtained to get equilibrium binding constant.49 The limitations of this method include
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requirement of large amount of sample, inability to obtain kinetic data, and nonapplicability to study systems with slower binding kinetics.50
1.5.5. Frontal analysis continuous capillary electrophoresis
Capillary electrophoresis can be used to characterize binding of weak affinity (KD
above 10-6 M) as long as protein/ligand complex has different electrophoretic mobility
compared to unbound protein. Frontal analysis continuous capillary electrophoresis
(FACCE)

involves

continuous

sampling

and

electrophoretic

separation.

The

electropherogram obtained from FAACE analysis shows multiple plateaus depending on
the components in the system, and the height of the first plateau is used to determine
the concentration of free protein to plot binding isotherms. FAACE have been applied to
deduce stoichiometry and binding constants of protein/polyelectrolyte interactions.50, 51
1.5.6. Affinity chromatography
Two methods based on affinity chromatography exist for qualitative analysis of
protein interactions. The first method involved use of affinity purification and mass
spectrometry for mapping protein interactions. This method involves tagging of a
protein followed by affinity purification of tagged-proteins and identification of the
eluted complexes using LC/MS/MS. This scheme failed to detect transient protein
complexes unless additional crosslinking is utilized.52
The second affinity chromatography based method was able to detect transient
protein complex. In this elution profiles were used to confirm binding (transient binding
of protein to the immobilized binding partner resulted in asymmetric elution profile).
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This technique was able to detect transfer of retinoic acid to retinoic acid receptor as it
formed a transient complex with immobilized holo CRABP II.53
1.5.7. Fluorescence based methods
The two most common fluorescence based techniques to quantitate protein
interactions in vivo include fluorescence resonance energy transfer (FRET) and
bimolecular fluorescence complementation. FRET is a non-radiative energy transfer
between an excited fluorophore (donor) and another fluorophore (acceptor), which
have overlapping emission/absorption spectra.54 For interacting proteins FRET occurs
when one protein labelled with an acceptor chromophore is in close proximity (10-80 Å)
with other protein labelled with donor chromophore. Bimolecular fluorescence
complementation is based on association of complementary protein fragments fused to
interacting domains of two proteins and give out a measurable fluorescence signal.55 A
major limitation of both of these techniques is it requires attachment of reporter
molecule to proteins, which could affect the structure of protein leading to inaccurate
binding data.
1.6.

Objectives
Biotherapeutics containing biopolymers have emerged to be very successful for

the treatment of chronic diseases. However, the increased heterogeneity of
biotherapeutics compared to small molecule drugs requires powerful and robust
analytical tools to characterize biotherapeutics at various levels. This work reports
multiple

novel

analytical

methods

that

utilize

synergy

of

non-denaturing

chromatography separation (IXC, SEC) and native ESI MS detection to characterize
15

biopolymer structure and interactions. Specifically the objectives include: (i) develop
SEC with online native ESI MS detection to characterize higher order structure of
proteins (oligomeric states and aggregates), and probe conformational integrity
(chapter 2); (ii) develop a label free method to measure kinetics and binding affinity of
transient protein interactions using SEC/native ESI MS (chapter 3); (iii) develop IXC with
online native ESI MS detection to characterize conformational integrity and positional
isomers of protein conjugates, and glycoforms of a biotherapeutic. Implement top-down
MS/MS in this online scheme for modifications wherein MS1 analysis could not provide
unequivocal confirmation (chapter 4); (iv) develop a IXC/ESI MS method to characterize
highly heterogeneous PEGylated glycoprotein (chapter 5).
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CHAPTER 2
CHARACTERIZATION OF SMALL PROTEIN AGGREGATES AND OLIGOMERS USING SIZE
EXCLUSION CHROMATOGRAPHY WITH ONLINE DETECTION BY NATIVE ELECTROSPRAY
IONIZATION MASS SPECTROMETRY
Peer-reviewed article published: Muneeruddin, K.; Thomas, J. J.; Salinas, P. A.; Kaltashov, I.A.;
Characterization of Small Protein Aggregates and Oligomers Using Size Exclusion
Chromatography with Online Detection by Native Electrospray Ionization Mass Spectrometry
Analytical Chemistry, 2014, 86, 10692 - 10699

2.1. Overview
Protein self-association is a key process in a variety of diverse phenomena
ranging from the highly ordered assembly of multiunit proteins into their functional
states to mostly chaotic aggregation. The latter gained considerable notoriety in the
past several decades due to its obvious role in the etiology of the so-called
conformational diseases, such as Alzheimer’s and Parkinson’s.56-58 Renewed interest in
protein aggregation in the biotechnology area is caused by the advent of protein
therapeutics, where aggregation affects not only the economy of the production
process but is also a cause of grave concerns vis-à-vis safety of biopharmaceutical
products.59, 60 The attention in this field has been traditionally focused on relatively large
subvisible aggregates, while small soluble oligomers were typically considered as
transient precursors to catastrophic aggregation. However, recent studies point out that
even reversible formation of very small oligomers (such as noncovalent dimers of
monoclonal antibodies) may have very negative consequences by interfering with the
drug delivery, which is triggered by increased formulation viscosity.61 The importance of
protein aggregation places a premium on developing robust analytical methods capable
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of detecting and characterizing protein oligomers across the entire aggregation
spectrum. Size exclusion chromatography (SEC) and, to a lesser extent, analytical
ultracentrifugation (AUC) are the most popular analytical tools capable of detecting
lower molecular weight oligomers, although their utility is often limited by inadequate
resolution.62 Light scattering42,

43, 63

and, more recently, small-angle X-ray scattering

(SAXS)64 are also enjoying popularity in this field, although data interpretation is
frequently model-sensitive, which limits their applicability to complex heterogeneous
systems.
Native electrospray ionization mass spectrometry (ESI MS) is another technique
that enjoyed rapid growth of popularity in the studies of protein associations in the past
two decades,34, 65, 66 with several recent examples highlighting its utility for the analysis
of small molecular weight aggregates of therapeutic proteins. In addition to providing
information on the stoichiometry of noncovalent protein complexes in solution, native
ESI MS allows the structural heterogeneity of protein therapeutics to be evaluated (by
analyzing mass profiles) and conformational integrity to be assessed (by analyzing ionic
charge state distributions).32 However, using native ESI MS to detect and especially
quantify noncovalent associations is not always straightforward, as artifacts are known
to be frequently produced during the ESI process, e.g., due to forced protein selfassociation during the final stages of charged droplets life when solvent evaporation
may result in a dramatic increase of the protein concentration.67 Other factors (e.g.,
nonlinear dependence of the response factors on solution composition) may also
complicate the quantitation efforts.68 Finally, presence of multiple oligomers in solution
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usually results in crowded mass spectra, where overlapping peaks representing different
oligomers can complicate the data interpretation and make it nearly impossible to
distinguish contributions from different species.
The ESI MS analysis of protein oligomers can be aided by SEC separation of small
aggregates based on their physical size. Such analyses can be carried out off-line by
collecting SEC fractions prior to their analysis,69, 70 but the results of such measurements
can be compromised due to the possibility of the composition changes of collected
fractions prior to MS analyses. For example, Heck and co-workers demonstrated that
the transient nature of the small aggregates of monoclonal antibodies may result in
their dissociation following fractionation by SEC;69 the opposite process where
additional protein oligomerization in collected fractions is triggered by desalting and
preconcentration is also possible.71 These problems can be circumvented by using online
MS detection for ESI MS, but because native ESI MS is typically less sensitive compared
to conventional ESI MS, acquisition of meaningful data on the chromatographic time
scale remained problematic until recently. As a result, the online SEC/ESI MS detection
scheme was only used for measuring the mass distribution of heterogeneous singlechain macromolecules, such as synthetic polymers,72, 73 antibodies74 and antibody-drug
conjugates,75 while the unique ability of native ESI MS to detect noncovalent biopolymer
complexes (such as an antibody–antigen complex) has not been utilized in such
analyses. However, the continuous improvement in ESI MS hardware has made it
possible to carry out measurements under near-native conditions using only minute
quantities of the analyte and relatively short acquisition time windows. We are taking
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advantage of these expanded capabilities of native ESI MS to use it as an online
detection tool for the analysis of noncovalent protein complexes (including both small
soluble aggregates and highly organized self-assemblies). This combination of two
powerful analytical techniques not only allows complex and heterogeneous protein
mixtures to be profiled vis-à-vis the presence of protein oligomers (based on both
retention time and mass information), but also enables assessment of protein
conformational integrity (based on ionic charge state distributions in ESI mass spectra).
Online detection with native ESI MS also allows meaningful information to be extracted
from

SEC

chromatograms

for

protein

assemblies

that

undergo

rapid

dissociation/reassociation on the chromatographic time scale.
2.2. Materials and Methods
Bovine serum albumin (BSA) and human transferrin (Tf) were purchased from
Calbiochem (La Jolla, CA) and Sigma-Aldrich Chemical Co. (St. Louis, MO), respectively. A
recombinant form of human arylsulfatase A (rhASA) was provided by Shire (Lexington,
MA). All other chemicals used in this work were of analytical grade or higher. BSA and Tf
solutions for online SEC/MS analysis were prepared by dissolving the protein powder
directly in 100 mM ammonium acetate without any desalting step. Analysis of rhASA
was carried out by diluting the drug substance sample in 100 mM ammonium acetate to
a required concentration (0.29 to 2.3 mg/mL), and pH adjusted to a desired level using
formic acid.
SEC separations were carried out using Agilent 1100 HPLC (Agilent Technologies,
Santa Clara, CA) equipped with a Waters (Milford, MA) Biosuite Ultra high resolution
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column (4.6 × 300 mm). Typically, 100 μL of a 1 mg/mL protein solution was injected
unless stated otherwise, and a 100 mM ammonium acetate solution (pH adjusted to a
desired level using either formic acid or ammonium hydroxide) was used as the mobile
phase in all separations at a flow rate of 0.1 mL/min. Upon exiting the column, the
eluate was directed to a UV absorption detector (operated at 280 nm) followed by
QStar-XL

(ABI-Sciex,

Toronto,

Canada)

hybrid

quadrupole/time-of-flight

mass

spectrometer equipped with a standard ESI source. The ESI source conditions were
optimized to provide a stable spray and optimal ion desolvation: drying gas, 30 L/min;
nebulizing gas, 39 L/min; curtain gas, 22 L/min; declustering potential on the skimmer,
290 V; declustering potential on the orifice, 160 V. The source temperature was
maintained in the 200–250 °C interval. Collisional cooling in the ion guide region (a gas
flow restricting sleeve in Q0) was used to enhance focusing and stability of noncovalent
complexes.
2.3. Results and Discussion
2.3.1. Conformational stability and aggregation propensity of a commercial protein
The ESI mass spectrum of bovine serum albumin (BSA) acquired under nearnative conditions (Figure 2.1) features a convoluted charge state distribution for ions
whose masses are consistent with BSA monomer (instead of a single mass, a distribution
of masses is observed, consistent with extensive nonenzymatic post-translational
modifications of the protein). A bimodal character of the charge state distribution of the
monomeric ions clearly suggests that conformational integrity of BSA is compromised:
either a fraction of the protein molecules is partially unfolded, or all BSA molecules
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undergo transient partial unfolding (native ESI MS alone cannot distinguish between
these two possibilities). The presence of partially unfolded protein molecules in the BSA
sample is not surprising, given the extent of nonenzymatic post-translational
modification of this protein (see the convoluted shapes of peaks of BSA ions in the mass
spectrum acquired under denaturing conditions, inset in Figure 2.1), which are known to
change the physical properties of proteins effecting the energy barrier between folded
and unfolded states (a detailed analysis of various forms of BSA from the commercial
sample reveals the occurrence of several nonenzymatic post-translational modifications,
such as cysteinylation, glycation, formation of pyridoxyl phosphate adducts, and several
others, as shown in Figure S1 in the Supporting Information). Furthermore, production
of commercial BSA was likely to include a thermal serum pretreatment process, which is
usually carried out to remove any bacterial or viral contamination in the sample.
Alternatively, the presence of partially unfolded BSA molecules in the native ESI
mass spectrum can be explained by invoking the notion of gas phase dissociation of
larger oligomeric ions. Should dissociation of metastable protein aggregates occur in the
gas phase, asymmetric charge partitioning is likely to generate highly charged
monomeric ions, a phenomenon reported in the past for other aggregation-prone
proteins. Ionic peaks corresponding to protein dimers and higher oligomers are indeed
observed in the higher m/z range (above 5000 u) of the BSA mass spectrum, and they
are also present at lower m/z range (below 3500 u). It is not clear, however, if these
ionic species represent dimers and higher oligomers existing in the protein solution at
equilibrium with monomers, or if their presence in the mass spectrum is an artifact
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related to forced association of proteins in rapidly shrinking electrosprayed droplets
documented by Klassen and co-workers. The size exclusion chromatogram of BSA (gray
trace in Figure 2.2) contains three peaks whose retention times are consistent with
monomeric (31.5 min), dimeric (27.6 min) and trimeric (25.7 min) forms of BSA,
although the earlier-eluting peaks could also be interpreted as partially unfolded protein
monomers. Therefore, neither native ESI MS nor SEC alone can provide unequivocal
characterization of the protein sample which is prone to both partial unfolding and
oligomerization.
The uncertainties regarding the data interpretation are readily resolved by
combining SEC separation with online native ESI MS detection. The appearance of the
total ion chromatogram (TIC) is consistent with the shape of the UV trace in that three
partially resolved peaks can be identified (Figure 2.2); however, the ability of MS to
identify ionic species giving rise to each TIC peak allows this chromatogram to be readily
interpreted. For example, only trimeric protein species are present in the earliest eluting
peak, allowing it to be assigned as a BSA trimer. Importantly, both high- and low-charge
density trimer ions are observed in the mass spectrum averaged across this peak (see
inset in Figure 2.2), indicating that BSA trimers undergo reversible and rapid (on the SEC
time scale) loss of compactness. A very similar behavior is exhibited by the protein
dimers, where both low-charge density ions (m/z > 5000 u) and high-charge density
ones (m/z < 3000 u) are prominent in the mass spectrum averaged across the second
SEC peak. No BSA monomers can be observed in either of the spectra averaged across
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the early eluting peaks, clearly indicating that the transient loss of higher order structure
within both dimers and trimers does not result in their dissociation.
The most prominent ionic species in the mass spectrum averaged across the
latest eluting SEC peak corresponds to BSA monomers. The charge state distribution is
bimodal, indicating presence of both compact and partially unfolded proteins.
Importantly, the extracted ion chromatograms for both high- and low-charge density
monomeric ions exhibit virtually indistinguishable elution profiles (right inset in Figure
2.2), which unequivocally demonstrates that the two forms of the protein are in rapid
equilibrium with each other, and their separation cannot be achieved by SEC alone. In
addition to the BSA monomers, the mass spectrum averaged across the latest eluting
peak contains contributions from oligomers. Because the extracted ion chromatogram
for these ions closely follows that of the monomeric ions in the 30–35 min time window,
these oligomers represent nonspecific association of proteins in rapidly shrinking
electrosprayed droplets in the ESI interface, a well-known artifact of ESI MS.76 Thus, SEC
with online native ESI MS detection not only provides a convenient way for detecting
and characterizing all protein species present in solution but also allows the ESI MS
artifact to be readily identified and eliminated from the analysis.
A very intriguing question that arises in connection with the analysis of BSA
oligomers is the nature of the protein/protein association that leads to their formation.
Although it is frequently assumed that these species are formed through noncovalent
interactions, the possibility of covalent interactions being involved in the early stages of
BSA aggregation cannot be excluded. Indeed, BSA has one free cysteine residue, which
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might participate in formation of external disulfide bonds (unless protected by
cysteinylation, as seen in at least some BSA molecules, see Figure S1 in the Supporting
Information). One can also argue that formation of higher oligomers may proceed
through disulfide scrambling leading to formation of multiple external disulfide bonds.
However, the ESI mass spectrum of BSA acquired under denaturing conditions does not
contain signals corresponding to protein dimers and tetramers, indicating the reversible
nature of the association process. Furthermore, dissociation under nonreducing
conditions is also evident in SEC chromatograms of oligomeric fractions of BSA (see
Figure S2 in the Supporting Information).
It is interesting to note that albumin in fresh human plasma does not exhibit
many features that are prominent in the mass spectra of commercial BSA. For example,
we note that the high-charge density peaks are absent from the ESI mass spectrum
acquired under near-native conditions, and the protein mass profile does not exhibit the
same high level of heterogeneity as BSA (see Figure 2.3). The two major forms
correspond to intact protein and cysteinylated protein,77 with all other forms being
relatively minor contributors. The mass difference between these two forms of albumin
is sufficient enough to allow extracted ion chromatograms for each of them to be
plotted separately, without the interference from the other form. The overlaid plots of
the two extracted ion chromatograms (for intact and cysteinylated human serum
albumin) display identical elution profiles, indicating that cysteinylation of the only free
cysteine residue in albumin does not compromise its conformational integrity (Figure
2.3). Unfortunately, the multiplicity of nonenzymatic PTMs observed in the commercial
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BSA sample does not allow adequate resolution to be achieved under the native
conditions to afford selective monitoring of these species in SEC/MS.
We note that the online analysis of BSA aggregates carried out in this work using
native ESI MS as a detection tool can also be accomplished using other tools, such as
multiangle light scattering (MALLS).63 However, as can be seen from the following
sections, SEC with online detection by native ESI MS has a unique advantage of being
able to provide meaningful information when analyzing coeluting proteins of different
masses, a task that remains very challenging for MALLS. One potential concern related
to the analysis of protein aggregates by SEC/MS is the use of volatile electrolytes (such
as ammonium acetate) as solvent systems. Although long-term exposure of proteins to
ammonium acetate or similar solvent systems may have the potential to affect their
aggregation propensity, the short time required for a single SEC/MS experiment makes
such changes unlikely. Indeed, comparison of aggregation profiles extracted from SEC
chromatograms acquired with ammonium acetate and a conventional phosphate buffer
as mobile phases revealed no differences outside of the experimental error (see Figure
S3 in the Supporting Information). The distribution of protein aggregates also appears to
be insensitive to the SEC flow rate (see Figure S4 in the Supporting Information), giving
indication that the measurements are unlikely to be affected by the shear flow around
the stationary phase particles.
2.3.2. Analysis of coeluting proteins
Analysis of protein mixtures where the difference in molecular weight (or, more
correctly, hydrodynamic radii) does not allow adequate chromatographic resolution to
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be achieved is a frequently encountered problem in SEC. The ability of online SEC/native
ESI MS to provide meaningful information for such systems was illustrated by analyzing
the equimolar mixture of BSA and human serum transferrin (Tf). The molecular weights
of these two proteins (66 and 80 kDa, respectively) are too close to each other to allow
satisfactory separation to be achieved using SEC. Indeed, the SEC chromatogram (UV
trace) shows a large peak with a convoluted shape consistent with the presence of two
abundant proteins having very close elution times (Figure 2.4, left panel). Although the
SEC alone fails to provide a clear distinction between BSA and Tf, online detection with
native ESI MS allows the elution profiles of both proteins to be determined (see the
extracted ion chromatograms for the +16 charge state of Tf and the +14 charge state of
BSA in Figure 2.4). The data presented in Figure 2.4 are also notable for another reason:
unlike BSA, ionic charge state distribution of Tf does not exhibit bimodal character, with
only low-charge density ion peaks present in the mass spectra (e.g., see the lower trace
in the right panel of Figure 2.4). This suggests that partially unfolded Tf molecules are
not present in the sample; incidentally, the SEC/MS data also fails to reveal the presence
of oligomeric forms of Tf (only BSA dimers and trimers could be observed, as shown in
Figure 2.4, right panel).
Another

important

observation

from

the

analysis

of

extracted

ion

chromatograms of BSA and Tf is that the elution order is not the same as the molecular
weight order (Tf is larger). Furthermore, Tf has a bilobal structure,78 whereas albumin
has a globular fold,79 which should make the difference in hydrodynamic radii even
larger. Nevertheless, the extracted ion chromatograms for BSA and Tf monomers clearly
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show shorter elution time for the former. Although it is possible that the longer
retention time of Tf molecules may be related to their interactions with the column
packing material beyond purely mechanical interactions (filtration), a more likely cause
for this anomalous behavior is the increase of the average hydrodynamic radius of BSA
monomers due to their transient unfolding during the separation process.
2.3.3. Characterization of protein self-association: arylsulfatase A
Both proteins considered in the previous sections (BSA and Tf) are monomeric,
and formation of oligomeric species is a clear sign of degradation. However, ordered
noncovalent association of several polypeptide chains is frequently required in order to
endow proteins with specific properties. Formation of the requisite quaternary structure
is frequently reversible, as is the case with arylsulfatase A, a critical lysosomal enzyme
that exits as a homodimer at neutral pH, but must assemble into octamers at mildly
acidic pH to avoid degradation by lysosomal proteases.22, 80 Recently, we demonstrated
that SEC correctly identifies homodimeric and homo-octameric arrangements as
quaternary structures of the recombinant form of human aryl sulfatase A (rhASA) at pH
7.0 and 5.0, respectively.81 However, SEC analysis of rhASA at intermediate pH (between
6.1 and 6.9) failed to provide conclusive results, yielding only broad unresolved peaks
whose profiles were both pH- and concentration-dependent, and the average elution
time did not match that of either dimers or octamers. At the same time, native ESI MS
analysis carried out within this intermediate pH region revealed the presence of only
dimeric and octameric species of rhASA,81 suggesting that the two forms of the protein
coexist at a dynamic equilibrium, and their interconversion (dissociation/reassociation)
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is very fast on the chromatographic scale, which does not allow these species to be
distinguished from one another by SEC.
Online SEC/ESI MS analysis of rhASA at the two terminal pH points (5.0 and 7.0)
confirms that the protein exists as an octamer and a dimer, respectively (Figures 2.5 and
2.6). Interestingly, the single peak in SEC chromatogram acquired at pH 7.0 (elution time
30 min) contains contributions from both dimeric and octameric ions, although their
elution profiles are indistinguishable (compare the extracted ion chromatograms for the
two groups of ions in Figure 2.6). This strongly indicates that the octameric ions of
rhASA observed at neutral pH do not reflect protein association in solution, but rather
represent the artifacts related to the forced association in the ESI interface, similar to
what had been observed for BSA (vide supra).
SEC/ESI MS analysis of rhASA carried out at intermediate pH 6.4 yields a total ion
chromatogram that also contains contributions from both octameric and dimeric ions
(Figure 2.7), although their respective extracted ion chromatograms differ from each
other in a very dramatic way. The elution profile of the octameric protein species is very
close to that recorded under the mildly acidic conditions (Figure 2.5). In contrast, the
elution profile of the dimers has a convoluted form with the elution front coinciding
with that of the octameric species, and tailing all the way to the elution window
observed for rhASA dimers at neutral pH (Figure 2.6). This significant dissimilarity of the
elution profiles of rhASA dimers and octamers observed at intermediate pH indicates
that the octameric species dissociate as they move through the column. Indeed, if we
denote the linear velocity of stable octamers and dimers as u8 and u2 (u8 > u2), which
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relate to the column length L and the observed elution times T8 and T2 (e.g., those seen
in Figures 2.5 and 2.6) as uk = L/Tk, then the elution time of the dimer t2 produced upon
dissociation of the octamer at time τdiss (τdiss < T8) can be calculated as
𝑡2 = 𝜏𝑑𝑑𝑑𝑑 +

𝐿−𝜏diss ∙𝑢8
𝑢2

𝑇

= 𝑇2 − 𝜏𝑑𝑑𝑑𝑑 ∙ �𝑇2 − 1�
8

(1)

In other words, the elution times of the dimers formed on the column will spread
between T8 and T2. The shape of this distribution can be used to determine the kinetics
of the octamer dissociation (e.g., to establish the distribution of τdiss), although no such
calculations were performed in this work due to insufficient chromatographic
resolution.
Dissociation processes alone do not account for all of the chromatographic features
observed in Figure 2.7: even though the extracted ion chromatogram of the octameric
species has a sharp frontal edge (similar top that seen in Figure 2.5), there is a small (but
measurable) delay in the elution. Furthermore, the shape of this chromatogram is
asymmetric, as a slight tailing toward longer elution times is observed (a feature that
was absent in the octamer elution profile in Figure 2.5). These two phenomena cannot
be explained without invoking the notion of reassociation of the products of dissociation
(dimers generated during the chromatographic run) to yield octamers. A simplified
mathematical treatment of the reassociation process can be carried out by assuming
that a new octamer is formed via association of four dimers, all of which were produced
at a single time point τdiss (i.e., by ignoring the possibility of multiple
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dissociation/reassociation events throughout a single chromatographic run). In this
case, the elution time of the newly formed octamer can be estimated as
𝑡8∗ = 𝜏𝑑𝑑𝑑𝑑 + 𝜏𝑟𝑟𝑟𝑟𝑟 +

𝐿−𝜏diss ∙𝑢8 −𝜏reass ∙𝑢2
𝑢8

𝑇

= 𝑇8 − 𝜏𝑟𝑟𝑟𝑟𝑟 ∙ �1 − 𝑇8 �
2

(2)

where τreass is the time interval between formation of the dimers and their reassociation
back to an octamer. Of course, a more rigorous mathematical treatment should take
into account the possibility of multiple dissociation/reassociation events, which would
require numerical simulations. Nevertheless, the simple algebraic expression 2 is useful
and informative as a way to rationalize the tailing of the elution profile of rhASA
octamer in Figure 2.7, and might be used to obtain a first-order approximation of the
distribution of τreass, especially under conditions when the extent of the dissociation
during the chromatographic run is limited.
Because the kinetics of the reassociation process should be concentration dependent,
one would expect to observe a shift in the elution front of the octameric species
following the decrease of protein concentration. Decrease in rhASA concentration from
2.3 to 1.1, 0.55 and 0.29 mg/mL (while keeping the acidity constant at pH 6.4) resulted
in a progressive decrease of the relative abundance of the octameric species and also
led to a noticeable change of their elution profiles (shift of the elution front to longer
times and enhanced peak tailing, see Figure 2.8), consistent with the expected
equilibrium shift toward the dissociation products when the overall protein
concentration goes down. A similar trend was observed under more acidic conditions
(pH 6.1), where total protein concentration reduction from 1.1 mg/mL to 0.29 mg/mL
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resulted in a monotonic decrease of the relative ionic signal of octameric species and a
shift of the octamer elution front (see Figure S5 in the Supporting Information).
It is important to note that even though the partial dissociation of rhASA octamers at pH
6.4 might be inferred from SEC alone by observing the trailing of the UV trace of SEC
chromatograms to longer elution times (e.g., see the brown trace in Figure 2.7), it is the
ability of MS to make a clear distinction between the dimeric and octameric ions that
allows the underlying cause of this peak broadening to be readily established. We also
note that the extent of peak broadening of the TIC is much more significant compared
to the UV trace, as dissociation of an octamer to four dimers does not change the UV
absorbance (as the total number of aromatic residues remains unchanged), while the
ionic signal increases (as the number of molecules capable of producing ions increases
4-fold).
Online detection with native ESI MS also allows another interesting phenomenon to be
observed, which relates to the uneven concentration profiles across chromatographic
peaks and is very important vis-à-vis establishing the realistic limits for the accuracy of
the SEC-based measurements. As has been already mentioned, kinetics of the
reassociation process are concentration-dependent (unlike octamer dissociation, which
is a unimolecular process). Therefore, it seems plausible that the octamer/dimer
equilibrium will be shifted toward the latter not only at the “far end” of the
chromatographic peak (as can be seen by comparing the elution profiles of octamers
and dimers in Figure 2.7), but also at the “front end” of the chromatographic peak.
Indeed, a careful analysis of the elution profiles of the two oligomeric species at the
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elution front provides unequivocal evidence that the dissociation process is strongly
favored during a very short time interval at the elution front (Figure 2.9). Indeed, while
the extracted ion chromatogram of the octameric species displays a monotonic
increase, reaches an apex and begins to decrease monotonically, the elution front of
dimers has a very sharp edge followed by a rapid drop in intensity (with the minimum
intensity for M2 coinciding with the apex of the M8 peak) before the “normal” behavior
is observed. The width of the aberrant peak at the front of the elution profile of dimeric
species defines the lower resolution limit for kinetic measurements that can be carried
with the SEC/native ESI MS.
2.4. Conclusions
The SEC/native ESI MS analysis of proteins and their assemblies presented in this work
provides an elegant way to characterize complex mixtures of proteins that include both
monomeric species, their low molecular weight soluble aggregates and larger
assemblies. A distinction can be readily made among the incompletely resolved proteins
based on their mass differences, and the analysis of protein ion charge state distribution
allows the conformational integrity to be assessed. The ability to resolve different
protein assemblies based on their masses allows a meaningful analysis to be carried out
when such species cannot be separated from one another by means of SEC alone due to
their rapid interconversion on the chromatographic time scale. Importantly, the new
technique does not require the protein samples to be purified/desalted prior to the
analyses, which makes it very appealing as a robust and powerful tool for the analysis of
biopharmaceutical products.
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FIGURES

Figure 2.1 ESI mass spectrum of BSA acquired under near-native conditions without SEC
separation of protein monomers and oligomers. The mass spectrum acquired under denaturing
conditions is shown in the inset (only 1000–2000 m/z range is shown, as no protein ions were
detected outside of this range).
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Figure 2.2 Online SEC/MS analysis of BSA: UV chromatogram (gray); TIC (black); extracted ion
chromatograms of the BSA monomers (blue, +14 charge state), dimers (magenta, a sum of +20
and +21 charge states) and trimers (brown, a sum of +25 and +26 charge states). Inset on the
left shows mass spectra averaged across the three SEC peaks (acquisition times are indicated
on each trace). Inset on the right shows extracted ion chromatograms of compact and partially
unstructured monomers (represented by low- and high-charge density ions).
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Figure 2.3 Extracted ion chromatograms for two forms of human serum albumin (intact, blue;
cysteinylated, red) in blood plasma. The inset shows the spectrum of the protein averaged
across the SEC peak and the zoomed view of the ion peak corresponding to +14 charge state
showing the protein mass distribution.
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Figure 2.4 Online SEC/MS characterization of an equimolar mixture of BSA and Tf: UV
chromatogram (black); TIC (gray); extracted ion chromatograms of the BSA monomers (blue, +14
charge state), BSA dimers (charge state +20, magenta) and Tf monomers (charge state +16, red).
Inset shows mass spectra averaged across the three SEC peaks (acquisition times are indicated
on each trace).
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Figure 2.5 Online SEC/MS of rhASA (1.1 mg/mL) at pH 5.0: UV chromatogram (brown), TIC
(black) and the cumulative extracted ion chromatogram of the octameric species (red). Inset
shows a mass spectrum averaged across the SEC peak.
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Figure 2.6 Online SEC/MS of rhASA (1.1 mg/mL) at pH 7.0: UV chromatogram (brown), TIC
(black) and the cumulative extracted ion chromatograms of the dimeric (blue) and octameric
(red) species. Inset shows a mass spectrum averaged across the SEC peak.
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Figure 2.7 Online SEC/MS of rhASA (2.3 mg/mL) at pH 6.4: UV chromatogram (brown), TIC
(black) and the cumulative extracted ion chromatograms of the dimeric (blue) and octameric
(red) species. Inset shows a mass spectrum averaged across the SEC peak.
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Figure 2.8 Elution profiles of the octameric species of rhASA acquired with online SEC/ESI MS at
pH 5.0, protein concentration 1.1 mg/mL (red trace) and pH 6.4, protein concentrations (from
top to bottom) 2.3, 1.1 and 0.55 mg/mL.
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Figure 2.9 Zoomed views of the elution profiles of octameric (red) and dimeric (blue) species of
rhASA acquired with online SEC/ESI MS at pH 6.4, protein concentration 2.3 mg/mL.
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Supplementary information

Figure S1. Mass profile of BSA from a commercial source deconvoluted from a mass spectrum
acquired under denaturing conditions.
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Figure S2. Elution profiles of unfractionated BSA (black trace) and re-injected fractions of
trimers (blue), dimer (red) and monomers (brown) showing dynamic character of low molecular
weight protein aggregates.
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Figure S3. Size distribution of BSA low molecular weight aggregates from SEC
chromatograms (UV detection only) acquired with ammonium acetate (left) and
phosphate buffer (right) as mobile phases. The colored bars represent monomers (brown),
dimers (red) and trimers (blue).
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Figure S4. Size distribution of BSA low molecular weight aggregates (top) and representative
SEC chromatograms (UV detection only) acquired at different flow rates.
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Figure S5. Elution profiles (extracted ion chromatograms) of the octameric species of rhASA
acquired with on-line SEC/ESI MS at pH 5.0, protein concentration 1.1 mg/mL (red trace) and
pH 6.1, protein concentrations (from top to bottom) 1.1 mg/mL, 0.55 mg/mL, 0.29 mg/mL
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CHAPTER 3
MEASURING KINETICS AND AFFINITY OF TRANSIENT PROTEIN-RECEPTOR
INTERACTIONS USING SIZE EXCLUSION CHROMATOGRAPHY WITH ONLINE NATIVE ESIMS DETECTION
3.1. Overview
Protein-protein interactions play an important role in diverse areas of life science
research including evaluation of cellular functions and also to aid in the development of
therapeutics. Due to this there has always been a tremendous need of analytical
methods to characterize and provide accurate information on kinetics and
thermodynamics of protein interactions.
Traditionally, strong interactions with the equilibrium dissociation constant (KD)
of low nM were favored (e.g., to develop drug molecules binding irreversibly with the
target enzyme for complete inhibition). Recently, there has been a shift towards
exploiting lower affinity interactions (the so-called transient protein interactions) with
KD in high nM – low µM range, due to their significance in proper functioning of living
cells and also for the development of targeted drug delivery systems.24, 25, 82 In the case
of drug delivery systems transient protein interactions help not only in efficient binding
of carrier protein to extracellular receptor, but also in its release after transporting
inside the cells. A strong binding in this case will have unfavorable consequences by
impeding the release of drug carrier from the protein receptor. Design of efficient
targeted drug delivery strategies also critically depends on the availability of the kinetic
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data, as the timing of the drug dissociation from its carrier is important for successful
delivery.
A wide variety of analytical methods have been developed to characterize
protein interactions, however owing to weak binding of transient protein interactions it
is technically difficult to detect them compared to stronger interactions. Some of the
most commonly used methods include surface plasmon resonance (SPR),83 analytical
ultracentrifugation (AUC),84 isothermal calorimetry (ITC),85 and tandem affinity
purification-mass spectrometry (TAP-MS).52 Majority of these methods have
disadvantages that invariably affect the binding characteristics such as requirement of
protein immobilization in SPR could alter structural properties of proteins, inability to
detect transient complexes in TAP-MS without any additional crosslinking, and large
concentration of proteins required for ITC and AUC. In vivo analysis of protein
interactions can be carried out using fluorescence based assays (e.g., fluorescence
resonance energy transfer (FRET) and bimolecular fluorescence complementation
(BiFC), however these methods require labeling of proteins with fluorophores, which
could again lead to a change in structure of protein.86 A limitation common to all of
these techniques is their inability to deal with highly heterogeneous systems frequently
encountered in the field of biotherapeutics.
In the past two decades native electrospray ionization mass spectrometry (ESI
MS) has enjoyed growing popularity to characterize structure of non-covalent protein
assemblies.34 In chapter 2, the advantages of combining separation by size exclusion
chromatography with native ESI MS detection to characterize aggregation,
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conformation, and rapidly equilibrating protein oligomers were presented.87 Although
relating ionic abundance of protein species with fractional concentration in solution is
not straightforward due to differences in their ionization and transmission efficiencies,
there have also been reports of using native ESI MS to quantify binding affinities.88
In this chapter a new label-free analytical method to measure kinetics and
binding affinity of transient protein interactions is reported. This method is based on the
SEC/native ESI MS method developed in chapter 2. Here we have developed a
mathematical model to explain the transfer of dynamic protein species through the
column, and by fitting the profile generated from this mathematical solution with the
extracted ion chromatograms (XICs) of SEC/MS binding and kinetic parameters of
transient protein interactions can be extracted. In this chapter first an explanation for
the elution behavior of recombinant arylsufatase A (rhASA) detected in chapter 2 is
given and then this is extended to protein/receptor interactions to obtain kinetics and
binding information. We have validated this method using known binding of transferrin
variants with soluble form of transferrin receptor.89, 90
3.2. Materials and Methods
Holo human transferrin (hTf) and holo bovine transferrin (bTf) were purchased
from Sigma-Aldrich Chemical Co. (St. Louis, MO). Soluble ectodomain transferrin
receptor (TfR), C-lobe and N-lobe of transferrin were generously provided by Prof. Anne
B. Mason (University of Vermont College of Medicine, Burlington, VT). Iron-free forms
(Apo) of transferrin were prepared by acid-denaturing the protein in the presence of
EDTA followed by centrifugal ultrafiltration (30k molecular-weight-cutoff vivaspin filters)
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to 100 mM ammonium acetate. All other chemicals used in this work were of analytical
grade or higher. Tf/TfR solutions were mixed in 2:1 molar ratio by diluting from stock
solution, and after equilibration were analyzed by SEC/ESI MS without any desalting
step.
SEC separations were carried out using Agilent 1100 HPLC (Agilent Technologies,
Santa Clara, CA) equipped with a Tosoh (Tokyo, Japan) TSKgel G3000 SWxl column (7.8 ×
300 mm) and a 100 μL injection loop. Ammonium acetate solution (100 mM, pH 7) was
used as the mobile phase in all separations at a flow rate of 0.5 mL/min. After exiting
the UV detector (operated at 280 nm), using a 1:1 flow splitter the flow rate of eluate
directed to ESI MS was set at 0.25 ml/min.
ESI MS detection was carried out using QStar-XL (ABI-Sciex, Toronto, Canada)
hybrid quadrupole/time-of- flight mass spectrometer equipped with a standard ESI
source. The ESI source conditions were optimized to provide a stable spray and optimal
ion desolvation: drying gas, 30 L/min; nebulizing gas, 39 L/min; curtain gas, 22 L/min;
declustering potential on the skimmer, 290 V; declustering potential on the orifice, 160
V. The source temperature was maintained in the 200 − 250°C interval. Collisional
cooling in the ion guide region (a gas flow restricting sleeve in Q0) was used to enhance
focusing and stability of noncovalent complexes.
3.3. Theory
In chapter 2 SEC/ESI MS analysis of recombinant arylsulfatase A (rhASA) at pH
6.4 yielded asymmetric peak shape for XICs of ocatmers (M8) and diffused pattern for
dimers (M2). This observation can explained by taking into account multiple dissociation
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events of octamers to dimers followed by re-association of newly formed dimers to
octamers over the fixed column length (L). This behavior is illustrated in figure 3.1 using
a 2-dimensional plot (distance traveled inside the column vs. the travel time). Taking
into consideration these dynamic reactions along with diffusion and mass transfer of
analytes a mathematical solution can be constructed for transfer of octamers and
dimers through the column as shown in equation 1. This system is a one-dimensional
version of the so-called advection-diffusion-reaction (ADR) equation,91 which is
frequently encountered in chemical engineering, the two significant differences being
unequal mass transfer coefficients uM8 and uM2 (the flow velocity is the same for all
reagents in a flow reactor), and non-linear reaction terms.
2

⎧ 𝜕𝐶𝑀8 = −𝑢 ∙ 𝜕𝐶𝑀8 + 𝐷 ∙ 𝜕 𝐶𝑀8 − 𝑘 𝐶 + 1 𝑘 𝐶2
𝑀8
𝑀8
−4 𝑀8
𝑀2
⎪ 𝜕𝜕
2
𝜕𝜕
𝜕𝜕2
2

𝜕𝐶𝑀2
𝜕2 𝐶𝑀2
⎨𝜕𝐶𝑀2
2
= −𝑢𝑀2 ∙
+ 𝐷𝑀2 ∙
⎪
2 + 4𝑘−4 𝐶𝑀8 − 2𝑘2 𝐶𝑀2
𝜕𝜕
𝜕𝜕
𝜕𝜕
⎩

(1)

(assuming a short lived intermediate tetramer (M4) during M2 ⇌ M8 transition of
rhASA)80

uM8, uM2: Linear velocity of octamers and dimers, respectively.

DM8, DM2: Diffusion coefficient of octamers and dimers, respectively.
Varying k2 and k-4 will generate a family of solutions for equation 1, from which
the best match with the experimental data will be selected, followed by generating
another family of solutions by varying the parameters k2 and k-4 within a narrower
range, etc. This optimization routine will eventually produce kinetic parameters that are
best fits for the experimentally measured XIC profiles of M8 and M2.
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In this chapter the approach presented above to study homo-oligomerization of protein
have been applied to protein/receptor interaction systems.
For protein and receptor that interacts to form a 1:1 complex (equation 2).
𝑘

𝑃 · 𝑅 ⇌𝑘−1
⇌𝑃+𝑅
1

(2)

The interacting partners (P, R, and P·R) have different size, and therefore would

travel with different linear velocities during trajectory inside the column. Due to this
difference the dissociation products generated in a single dissociation event will not be
able to re-associate (as shown in figure for a hypothetical protein receptor system).
However, physical interaction leading to reassociation of P and R will be possible if their
trajectories intercept as they are formed in two different dissociation events (grey
circles in figure 3.2). The partial derivative equations describing dynamic P·R complex is
a simple extension of equation 1:
𝜕𝐶
𝜕 2 𝐶𝑃𝑃
𝜕𝐶
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+ 𝑘−1 𝐶𝑃𝑃 − 𝑘1 𝐶𝑃 𝐶𝑅
𝜕𝜕
𝜕𝜕
𝜕𝜕2
𝜕𝐶𝑅
𝜕𝐶𝑅
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+ 𝑘−1 𝐶𝑃𝑃 − 𝑘1 𝐶𝑃 𝐶𝑅
𝜕𝜕
𝜕𝜕
𝜕𝜕2

(3)

Partial derivative equations 5 are a straight forward modification of equation 3 for
bivalent system in which the receptor (R) can bind to two protein molecules
𝑘

𝑘

𝑃2 𝑅 ⇌𝑘−2
𝑃 + 𝑃 · 𝑅; 𝑃 · 𝑅 ⇌𝑘−1
𝑃+𝑅
2
1

(4)
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3.4. Results and Discussion

SEC/ESI MS analysis of non-covalent protein assemblies stable in solution on the
chromatographic time scale give rise to well-defined peaks whose elution time is
consistent with the hydrodynamic size (also controlling the linear velocity) of each
species. An example is shown in figure 3.3, where incubation of the metalloprotein
transferrin (Fe2Tf) with the soluble ectodomain of transferrin receptor (TfR) resulted in
formation of a stable 2:1 complex, detected as an earlier eluting peak. In this case online
detection with native ESI MS provides confirmation based on their masses (i.e., an earlyeluting 322 kDa (Fe2Tf)2·TfR complex, and a late-eluting 79 kDa Fe2Tf, which was present
in the mixture in molar excess). A failure to form a protein/receptor complex would be
confirmed by the absence of the early-eluting species in the chromatogram, as
illustrated in Figure 3.3 for the mixture of TfR and Tf N-lobe (Tf loses its receptor-binding
competence upon removal of the C-lobe).89
3.4.1. Protein-receptor complex interacting with 1:1 stoichiometry
A model system of 1:1 complex was made by mixing molar excess of C-lobe form
of human transferrin (FeTfC) with transferrin receptor (TfR), which has already been
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shown using orthogonal approaches to have a weak affinity.89, 90 As shown in figure 3.4
the XICs obtained from the SEC/ESI MS analysis of this mixture is convoluted. The XIC
behavior of free FeTfC and 1:1 complex (FeTfC·TfR) follows the pattern shown in figure
3.2; FeTfC·TfR complex peak (purple trace in figure 3.4) is asymmetrical with significant
tailing and the dissociation products that fail to re-associate appear in chromatograms
as early eluting free FeTfC molecules (16.1 – 17.5 min interval).
Figure 3.5 illustrates a family of solutions generated for each of the interacting
species (blue - FeTfC, red - TfR, and purple - FeTfC·TfR complex) using equation 3.
Symmetrical peaks shapes with elution time characteristic of their linear velocity were
generated, when dissociation channels were turned off. Opening only the dissociation
path for the complex (k-1 = 0.015) shows distinct features that include decrease in
abundance FeTfC·TfR complex peak, increase in abundance and broadening of TfR peak,
and monotonic trailing of FeTfC to early elution time interval. Opening both dissociation
and association of complexes (k1 = 1.3.104 and k-1 = 0.020) led to tailing and shift of
FeTfC·TfR complex to later elution time as these complexes are formed as a result of
reassociation of interacting partners on the column, and a bimodal trailing of FeTfC was
also seen.
Based on these observations a family of solutions were generated to get a close
match fit with experimental chromatograms (figure 3.6). In our optimization steps a
solution was considered a match if its peak shape and elution time aligned with the
experimental chromatograms. As TfR signal was not recorded, we have used
chromatograms of FeTfC and FeTfC·TfR complex to get a match. By not taking absolute
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abundance of each of these species into consideration, any artifacts generated due to
differences in ionization and transmission efficiency are avoided. Following this
optimization routine for FeTfC and TfR interaction, we detected kinetic rates of k1 = 3.3 x
107 M-1 min-1and k-1 = 3.0 min-1. This gives an equilibrium dissociation constant of 90nM.
3.4.2. Protein-receptor complex interacting with 2:1 stoichiometry
Validation of this method to characterize binding of a 2:1 protein/receptor
complex was carried out using transferrin variants. The affinity of these transferrin
variants to human TfR has already been reported to cover a broad range using
orthogonal approaches.89 Figure 3.7 illustrates experimental data for binding of three
transferrin variants; apo human transferrin (hTf), holo bovine transferrin (Fe2 bTf), and
apo bovine transferrin (bTf) interacting with TfR. These chromatograms are highly
convoluted and differ significantly from those detected for Fe2hTf/TfR interaction (figure
3.3). First, Tf·TfR complexes of both 2:1 and 1:1 stoichiometries are observed despite
excess of the protein over the receptor in the injection mixture. Second, the elution
profiles of the 2:1 complexes (Tf2·TfR) are asymmetrical and are shifted compared to the
elution time of the (Fe2hTf)2·TfR complex (shown in Figure 3.7 with a dotted line). This is
consistent with the notion of the vast majority of 2:1 complexes not surviving the
chromatographic run and dissociating prior to elution from the column; the observed
complexes are formed within the column as a result of re-association processes. The
second, third… generation of dissociation products that fail to re-associate appear in
chromatograms in Figure 3.7 as early eluting free Tf molecules (14.5 – 17.5 min interval)
and 1:1 complexes.
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Generating a family of solutions for (Tf)2·TfR, Tf·TfR, and Tf species using equation 5 and
optimizing them by varying kinetic rate constants (k1, k-1, k2, and k-2) yielded a close
match profile as shown in figure 3.8. Based on these kinetic rates, equilibrium
dissociation constants were obtained for transferrin variants used in this validation
study. As expected the equilibrium dissociation constants (KD1 and KD2) for hTf and Fe2
bTf were in higher nano molar range, and very weak binding with KD1 in micro molar and
KD2 in higher micro molar for interaction of bTf with human TfR was detected.
3.5. Conclusions
A label-free method using SEC with online ESI MS to obtain kinetic and thermodynamic
parameters of transient protein interactions has been presented. Strong protein
complexes that do not dissociate on the chromatographic timescale will be outside of
reach of this method. In this study we have validated this new method for transient
protein

interactions

(protein/receptor

complexes)

with

both

1:1

and

2:1

stoichiometries. In a similar way this method can also be extended to transient protein
interactions with higher stoichiometries as long as each of the interacting species have
distinct linear velocities in chromatography.
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FIGURES

Figure 3.1 Schematic 2-D diagram illustrating behavior of M8 and M2 species during the SEC
analysis of metastable rhASA octamers. Stable species would travel only along the trajectories
on the far left (M8) and far right (M2), but the actual trajectories branch out as a result of M8
dissociation (white circles) and M2 re-association (gray circles). Red and blue circles show
elution of M8 and M2, respectively.
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Figure 3.2 Illustration of behavior of two interacting species (P, protein, and R, receptor) during
the SEC run. All three species are present at the time of injection. Products of P·R dissociation
(white-filled circles) can re-associate with finite probability only if their trajectories intercept
(gray circles).
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Figure 3.3 SEC and SEC/ESI MS characterization of transferrin binding to its receptor with high
affinity (full-length, iron-saturated human Tf, top) and failing to form a complex with the
receptor (N-terminal half of human Tf, bottom). The three traces show UV chromatograms of Tf,
TfR and their mixtures. Extracted ion chromatograms of the protein/receptor complex (purple)
and the protein alone (blue) are also shown.
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Figure 3.4 SEC/ESI MS characterization of C-lobe form of transferrin (FeTfC) binding to
transferrin receptor (TfR). The three traces show UV chromatogram (grey), and extracted ion
chromatograms of FeTfC (blue) and FeTfC·TfR complex (purple).
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Figure 3.5 Family of solutions generated using initial set of rate constants as shown in
each panel. The three traces show extracted ion chromatograms of FeTfC (blue), TfR
(red), and FeTfC·TfR complex (purple). Filled blue and red traces (extracted ion
chromatograms of FeTfC and TfR, respectively at k1, k-1 = 0) are overlaid in middle and
bottom panel to illustrate change in peaks under different rate constants.

62

Figure 3.6 Extraction of rate constants for FeTfC/TfR binding and dissociating using experimental
SEC/ESI MS data. The calculated elution profiles are overlaid to get the best match. Calculated
profile using rate constants of k1= 3.3 x 107 M-1 min-1and k-1 = 3.0 min-1 (green) was considered
to be the best match with the experimental SEC/MS data.
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Figure 3.7 SEC/ESI MS analysis of transient Tf/TfR complexes. Tf elution profiles are shown with
blue curves, and elution profiles of Tf·TfR complexes are shown with orange (1:1 stoichiometry)
and purple (2:1) curves. The receptor affinity order is apo-human Tf > holo-bovine Tf >> apobovine Tf.
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Figure 3.8 Extraction of rate constants for Tf/TfR binding and dissociating using
experimental SEC/ESI MS data. The calculated elution profiles that were good match with
experimental data are shown. Calculated elution profile of Tf (solid black trace), Tf·TfR
complexes with 2:1 stoichiometry (solid purple trace), and 1:1 stoichiometry (solid orange
trace) for each experiment are shown. Rates constants; k1 and k-1 are expressed in M-1
min-1 and min-1, respectively.
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CHAPTER 4
CHARACTERIZATION OF INTACT PROTEIN CONJUGATES AND BIOPHARMACEUTICALS
USING ION-EXCHANGE CHROMATOGRAPHY WITH ONLINE DETECTION BY NATIVE
ELECTROSPRAY IONIZATION MASS SPECTROMETRY AND TOP-DOWN TANDEM MASS
SPECTROMETRY
Peer-reviewed article published: Muneeruddin, K.; Nazzaro, M; Kaltashov, I.A.; Characterization
of Intact Protein Conjugates and Biopharmaceuticals Using Ion-Exchange Chromatography with
Online Detection by Native Electrospray Ionization Mass Spectrometry and Top-Down Tandem
Mass Spectrometry Analytical Chemistry, 2015, 87, 10138 – 10145

4.1. Overview
Protein therapeutics remain the fastest growing segment in the pharmaceutical
industry,5 and as the number of both approved biopharmaceutical products and those
still in various development stages continue to grow, so does the demand for powerful
and robust analytical technologies capable of comprehensive characterization of these
complex molecules. Protein therapeutics are inherently less stable compared to
traditional small-molecule medicines, as their large size (and, consequently, a large
number of chemically labile sites) makes them prone to a variety of nonenzymatic posttranslational modifications (PTMs), many of which impact both therapeutic and safety
profiles of the protein drugs. This is usually a result of conformational changes triggered
by chemical modifications, although a loss or alteration of the higher order structure
may also be precipitated by environmental factors, such as temperature variations and
exposure to solvent–air interface. Therefore, complete structural characterization of
biopharmaceutical products cannot focus solely on their covalent (primary) structure
but must also address the higher order structure, including conformational integrity and
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in the case of multiunit proteins correct noncovalent assembly. Demanding and
challenging as they are, these tasks are further complicated by structural heterogeneity
inherent to many protein-based therapeutics (e.g., due to extensive glycosylation).
Lastly, a large number of the second-generation biopharmaceuticals contain “designer”
modifications (such as protein–drug or protein–polymer conjugates), which increase the
extent of heterogeneity even further due to variation in the extent of conjugation
(loading) and the presence of multiple positional isomers within the population of
conjugates with fixed stoichiometry.
Obviously, comprehensive characterization of such complex systems is a very tall
order, and analytical techniques capable of not only detecting and quantitating
nonenzymatic PTMs within highly heterogeneous protein therapeutics but also
assessing the impact of these modifications on conformational integrity are at premium.
Mass spectrometry (MS) has recently emerged as a very powerful and robust tool to
characterize biopharmaceutical products at a variety of levels ranging from mass
profiling,92 amino acid sequencing,93,
integrity20,

21, 98

94

and PTM mapping95-97 to conformational

and aggregation propensity.70,

99, 100

While the benefits of MS for

comprehensive characterization of biopharmaceutical products have been welldocumented,32,

33, 101

the growing demands of characterizing ever more complex

protein-based therapeutics continue to stimulate development of new analytical
methodologies. Use of hyphenated techniques, such as liquid chromatography/mass
spectrometry (LC/MS) and liquid chromatography/tandem mass spectrometry
(LC/MS/MS), has proved particularly useful for characterization of complex protein
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samples both in the field of biopharmaceuticals and beyond;102-104 however, the vast
majority of applications make use of reversed-phase chromatography as the separation
step. While the versatility of reversed-phase LC allows it to be applied for separations of
both small peptides and large intact proteins, the nature of the mobile phase causes the
proteins to be unfolded during the separation step. As a result, any information on the
higher order structure (polypeptide chain folding and/or noncovalent assembly of
multiunit protein complexes) is lost, and the MS analysis is focused exclusively on
covalent structure.
In contrast to reversed-phase LC, ion-exchange chromatography (IXC) and size
exclusion chromatography (SEC) can employ nondenaturing conditions during the
separation process, and in fact SEC is frequently used in the biopharmaceutical sector
for assessment of the higher order structure.105,

106

IXC has also proved to be a very

useful tool for characterization of complex biopharmaceuticals;107 however, neither of
these two techniques is used routinely in combination with online electrospray
ionization (ESI) MS detection. As pointed in a recent review, “while the simplicity
associated with size exclusion and cation-exchange chromatography make them ideally
suited for routine use, the inherent complexity of mass spectrometry restricts its use to
characterization, this despite its richness in information.”102 Recently, we demonstrated
that SEC/MS can in fact be used for characterization of complex biopharmaceutical
products, yielding not only mass profiles, but also information on conformational
integrity, aggregation propensity, and quaternary structure;87 the benefits of using
SEC/MS for mass profiling of heterogeneous protein therapeutics have also been
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documented.75, 108 The use of IXC with online MS detection has also been demonstrated
recently,109 although the spray conditions in the ESI interface resulted in protein
unfolding prior to entering MS. Consequently, all information on protein conformation
was inferred from the chromatographic elution time,109 rather than from ESI mass
spectra.
In this work we present an online IXC/ESI MS in which the ESI source is operated
under nondenaturing conditions (the so-called native ESI). Using native ESI MS as a
detection tool allows the capability of the detector to be expanded beyond mere mass
profiling by allowing the conformational integrity of various species to be assessed
based on the analysis of protein ion charge state distributions in the mass spectra.110
Furthermore, incorporation of top-down fragmentation in the experimental workflow
(LC/MS/MS of whole proteins) allows nonenzymatic PTMs to be identified in situations
when the mass measurement alone is not sufficient for an unequivocal conclusion to be
reached. Although this initial report focuses on proteins of relatively modest size (not
exceeding 25 kDa), this technique appears to be ideally suited for the analysis of large
systems as well, including antibody–drug conjugates (ADCs) and multiunit protein
assemblies.
4.2. Materials and Methods
Chicken egg white lysozyme (Lz), dithiothreitol (DTT), and iodoacetic acid (IAA)
were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO), and N-succinimidyl-Sacetylthioacetate (SATA) was purchased from Pierce Biotechnology (Rockford, IL). Lz
was conjugated with SATA using a previously described procedure.111 Briefly, SATA
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(prepared in DMSO) was added to Lz in phosphate buffer (pH 7.0) such that the ratio of
SATA to number of primary amine sites in lysozyme was 1:1. The mixture was incubated
at 37 °C for 90 min to allow for conjugation reaction to occur and stored at −20 °C prior
to characterization. Complete reduction of Lz (all four disulfide bonds) was carried out
by following a previously described procedure112,

113

that was modified to avoid

precipitation of the (partially) reduced forms. Lz (1 mg/mL) was incubated in the
presence of 50 mM ammonium bicarbonate (pH 8.0), 30% acetonitrile, and 20 mM DTT
(freshly prepared in water) at 30 °C for 20 min. Following reduction, free cysteine
residues were alkylated by adding IAA to a final concentration of 40 mM and incubating
at room temperature for 30 min. Prior to the analyses, the pH of both freshly reduced
and alkylated Lz solutions was adjusted to 7.0. Selective reduction and alkylation with
IAA of a single disulfide bond, Cys6–Cys127, was carried by following the published
protocol113 using lower DTT content (the so-called CM-lysozyme113). A stressed sample
of raw interferon-β was provided by Biogen (Cambridge, MA). All other chemicals used
in this work were of analytical grade or higher.
Ion-exchange chromatography was performed on an Agilent 1100 HPLC (Agilent
Technologies, Santa Clara, CA) equipped with a 2.1 mm × 250 mm weak cation-exchange
column PolyCAT A (PolyLC Inc., Columbia, MD), particle size of 5 μm and pore size of
1000 Å. Ammonium acetate at pH 7.0 was used for MS-compatible gradient elution (100
mM in mobile phase A and 1 M mobile phase B). The total flow rate was maintained at
0.1 mL/min (SATA-conjugated Lz and CM-lysozyme) or 0.2 mL/min (fully reduced Lz and
stressed interferon-β1a). The specific linear gradient depended on the sample analyzed
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(vide infra), but never exceeded 60% mobile phase B. Upon exiting the column, the
eluate was directed to a UV absorbance detector (operated at 280 nm) followed by
online detection by native ESI MS without any solvent modification or flow splitting
using a QStar-XL (ABI-Sciex, Toronto, Canada) hybrid quadrupole/time-of-flight mass
spectrometer (for the analysis of SATA-conjugated and reduced Lz) or Synapt G2Si
(Waters, Milford, MA) hybrid quadrupole/time-of-flight mass spectrometer (for the
analysis of stressed interferon-β). The ESI source conditions were optimized to get a
stable spray and efficient desolvation of analyte ions. For Qstar XL the conditions were
as follows: drying gas, 37 L/min; nebulizing gas, 30 L/min; curtain gas, 22 L/min;
declustering potential on the skimmer, 290 V; declustering potential on the orifice, 160
V. The source temperature was maintained in the 200–250 °C interval. For Synapt G2Si
the conditions were optimized as follows: sampling cone, 40 V; source offset, 80 V;
desolvation temperature, 400 °C; cone gas flow, 45 L/h; desolvation gas flow, 600 L/h.
Online top-down fragmentation of protein ions was carried out with Synapt G2Si using
both electron-transfer dissociation (ETD) in the trap cell and collision-induced
dissociation (CID) in the transfer cell. For ETD the trap wave height was set at 1.0 V, and
trap wave velocity was 300 m/s. CID was carried out by setting collision energy in the
transfer cell to 100 and transfer gas flow rate to 4.3 mL/min. Postacquisition processing
was carried out with the Origin data analysis software (Origin Lab Corp., Northampton,
MA).
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4.3. Results and Discussion
4.3.1. Initial evaluation of online IXC/ESI MS: characterization of complex protein
conjugate samples
The utility of IXC/ESI MS for characterization of heterogeneous protein samples
was initially evaluated using SATA-activated Lz. SATA is a short-chain reagent targeting
primary amines, which is used to introduce a sulfhydryl group to proteins. While SATA is
frequently used in the studies of protein higher order structure as a cross-linking
reagent,114 our own interest in this reagent stems from its use as a coupling agent to
produce transport protein/payload protein conjugates to enable targeted delivery.111
Since SATA is an amine-targeting reagent, and most proteins contain at least several
such groups (i.e., α-amine at the N-terminus and ε-amines of lysine side chains), we
frequently observe formation of multiple conjugates, which differ in the extent of
conjugation. Low conjugation yields result in poor efficiency of protein cross-linking,
while extensive conjugation (placing of multiple sulfhydryls on the protein surface) leads
to protein polymerization; hence, controlling the extent of conjugation becomes
important, which can be readily achieved by measuring the masses of the conjugation
products.111 However, mass measurements alone fail to characterize another dimension
of protein conjugate heterogeneity, namely, the presence of positional isomers within
the ensemble of protein species having identical conjugation stoichiometry. Ideally, one
aims at producing relatively homogeneous population of conjugates (e.g., by taking
advantage of pKa difference between α- and ε-amines and carrying out the reactions
within the pH range where a difference in their reactivity exits), and the ability to
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monitor protein heterogeneity due to the presence of positional isomers would
obviously be very valuable for optimizing the conjugation protocol.
Previously we used straightforward ESI MS to evaluate the extent of modification
of Lz with SATA,111 while assessing the distribution of conjugation sites among seven
possible candidates within this protein required the use of a time-consuming and laborintensive procedure that involves proteolytic digest and

18

O labeling of fragment

peptides followed by LC/MS and LC/MS/MS analyses (S. Nguyen et al., in preparation).
IXC/ESI MS analysis of SATA-activated Lz at the whole-protein level (Figure 4.1) provides
an elegant alternative by allowing both the extent of conjugation and the presence of
positional isomers to be determined in a single experiment. While in this particular
sample (prepared by using a 1:8 protein/SATA ratio) the extent of conjugation varies
from 0 (intact, unmodified Lz) to 4 (SATA4·Lz), only these two species have extracted ion
chromatograms with single peaks (52 and 30 min, respectively). The extracted ion
chromatogram of SATA·Lz displays two major and two minor peaks (teal-filled curve in
Figure 4.1), consistent with the notion that at least four out of seven possible amines
participate in conjugation. The numbers of peaks in extracted ion chromatograms of
SATA2·Lz and SATA3·Lz (six and four, respectively) are also consistent with the notion of
four amines targeted by SATA. This relatively straightforward analysis allows a
conclusion to be made that, while the conjugation reaction does not occur at a single
site within the protein, the number of participating amines is limited (four out of seven).
Importantly, this conclusion could not be made based on either chromatographic or MS
data alone. Using ESI MS as a detection tool also allows a distinction to be readily made
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among coeluting species with different conjugation stoichiometries (e.g., SATA·Lz and
SATA2·Lz at 39.5 min, and SATA2·Lz and SATA3·Lz at 37 min).
While it may be tempting to use the peak heights of various species detected in
IXC/ESI MS analysis of the SATA/Lz conjugates for their quantitation, it should be
remembered that the intensity of the ionic signal in ESI MS depends on a variety of
parameters, including solvent composition115 (which is a function of time, since a
gradual elution is used) and the presence of other coeluting species.116 Nevertheless,
examination of the UV trace and individual extracted ion chromatograms presented in
Figure 4.1 suggests that a reasonably good agreement exists between the UV
absorbance and the ionic signal throughout the entire chromatogram (based on peaks
resolved in the UV chromatogram, the deviation of relative UV and extracted ion
chromatogram (XIC) peak intensities does not exceed 15%; see the Supporting
Information for more information). Therefore, extracted ion chromatograms appear to
be well-suited for at least semiquantitative assessments of relative abundances of
various protein species present in the sample.
4.3.2. Online IXC/ESI MS provides information on protein conformational integrity
Above and beyond providing mass information on various protein conjugates,
ESI MS detection allows large-scale conformational changes to be detected based on the
analysis of protein ion charge state distributions. Mass spectra of all SATAn·Lz species
detected in the experiment shown in Figure 4.1 are similar to each other in that only low
charge density ions are present in the spectra (charge states ranging from +5 to +8
populating the high m/z regions of the mass spectra). These narrow charge state
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distributions are nearly identical to that of the intact (unconjugated) Lz (blue trace in
Figure 4.1), suggesting that even multiply conjugated protein molecules maintain
compact structure in solution.110
In order to prove that large-scale unfolding can in fact be detected by IXC with
online detection by native ESI MS, this technique was applied to characterize a mixture
of intact Lz and fully reduced and alkylated Lz (Figure 4.2). The mixture contains only
two species that can be readily identified based on their masses: reduction of all four
disulfide bonds followed by alkylation of free sulfhydryls leads to a mass increase of 464
Da (this species eluted at 15 min); no partially reduced Lz species (expected masses
14 421, 14 537, and 14 653 Da) were observed. An important distinction between the
two mass spectra averaged across the peaks representing fully reduced (15 min) and
intact (43 min) Lz is the appearance of the ionic charge state distributions (inset in
Figure 4.2): the low m/z region of the mass spectrum collected at 15 min clearly
contains abundant ions suggesting that the protein eluted at this time undergoes
(partial) unfolding in solution. This, of course, is not surprising, as complete reduction of
disulfide bonds in Lz is known to compromise its higher order structure,112 which is
reflected in the ionic charge state distribution in native ESI MS.
In contrast to the completely reduced Lz species, removal of a single disulfide
bond Cys6–Cys127 (which can be selectively reduced) has little effect on the structure and
activity of native Lz.113 We used this three disulfide containing derivative of Lz (CMlysozyme) to demonstrate that the ionic charge state distributions do reflect protein
conformation in solution, rather than diminished stability in the gas phase due to a loss
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of an internal cross-link, and that IXC/ESI MS does not generate false positives regarding
loss of protein conformational integrity. The CM-lysozyme sample in which the Cys6–
Cys127 disulfide bond was selectively reduced based on existing protocols113 was
analyzed by IXC/ESI MS, revealing three components (Figure 4.3). These species were
readily identified based on their masses: CM-lysozyme eluting at 36 min (mass 14 421
Da), intact Lz eluting at 52 min (mass 14 305 Da), and a minor component eluting at 40
min whose mass (14 363 Da) is consistent with a single alkylation event (most likely
representing a product of a side reaction, where a fully oxidized Lz species is alkylated at
a histidine side chain, which is known to be marginally reactive with IAA)117. Importantly,
the ionic charge state distributions for all three detected Lz species are essentially
identical, and no ionic signal is observed in the low m/z regions of the mass spectra (see
inset in Figure 4.3). This is in excellent agreement with the notion of the Cys6–Cys127
disulfide bond not being critical for the conformational stability of this protein,118
providing additional evidence that IXC/ESI MS can be used not only for identification of
various protein forms in complex mixtures based on their masses, but also for assessing
their conformational integrity based on their ionic charge state distributions.
4.3.3. Characterization of heterogeneous protein therapeutics with IXC/ESI MS and
online protein ion top-down fragmentation: identification of stress-induced
modifications in Interferon-β
Evaluation of IXC/ESI MS for the analysis of complex biopharmaceutical samples
was carried out using a stressed sample of interferon-β, a protein drug that is used for
treatment of multiple sclerosis.119 While historically the first form of interferon-β that
became available for clinical use was homogeneous, as it was expressed in bacteria and
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was carbohydrate-free,120 the presence of carbohydrates is known to improve the
activity of this protein therapeutic significantly by enhancing its stability.121,

122

Not

surprisingly, just like many other glycoproteins, interferon-β expressed in mammalian
cells exhibits a significant extent of heterogeneity due to the presence of multiple
glycoforms.123 While more homogeneous preparations of this protein can be achieved
using either extensive fractionation/purification or methods of molecular biology,124 in
this work we intentionally used raw protein material to have the highest degree of
heterogeneity in the analytical sample. Furthermore, the sample was stressed to induce
nonenzymatic PTMs (deamidation) on the background of extensive enzymatic PTMs
(glycosylation). Mass profiling of this sample carried out by ESI MS reveals the presence
of six major glycoforms that can be distinguished from one another based on their
masses (see inset in Figure 4.4). This number appears to agree with the number of
partially resolved peaks observed in both UV and TIC chromatograms of the interferon-β
sample analyzed by IXC (Figure 4.4), although the signal intensity distribution of
chromatographic peaks does not match that of the ionic signals of different glycoforms
in the mass spectrum of the sample prior to separation.
The reason for this discrepancy becomes obvious when XICs are plotted for each
of the six major glycoforms (color-fitted curves in Figure 4.4) and overlaid with the TIC.
Intriguingly, each glycoform identified by ESI MS gives rise to two peaks in the
chromatogram of the protein sample (e.g., the protein species whose mass is consistent
with interferon-β bearing a BiNA2 carbohydrate chain elutes at both 17.5 and 19 min,
and analogous behavior is exhibited by all other glycoforms). Although there must be a
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significant difference between the two species to cause the elution time change, the
mass measurement alone in this case is not sufficient for this difference to be identified.
There are three nonenzymatic PTMs causing only minimal mass difference that could
conceivably occur as a result of protein stress: disulfide reduction (mass difference
between the intact and the modified protein 2 Da), deamidation (1 Da), and disulfide
scrambling (0 Da). The protein mass changes caused by these PTMs are very small
(<0.01% of the total mass) and can easily evade MS detection, while the underlying
chemical changes might be sufficient to afford a notable change in IXC elution time.
Since the disulfide bridge in interferon-β is important for maintaining its tertiary
fold, its complete reduction would be expected to cause partial unfolding; a putative
scrambling event (formation of a non-native disulfide bridge involving free cysteine
residue at position 17) would also be expected to alter the protein conformation. At the
same time, deamidation events125 frequently do not induce large-scale conformational
changes.126 The charge state distributions for BiNA2 species of interferon-β eluting at
17.5 and 19 min were nearly identical to each other, both featuring only low charge
density ions (in the high m/z region of the mass spectra). Therefore, a conclusion was
made that both forms of the protein maintained compact structure in solution, and the
stress-induced nonenzymatic PTMs failed to result in large-scale conformational
changes. While this seems to suggest that the modification in question is in fact
deamidation, a more definitive proof was needed to unequivocally confirm the presence
of the deamidated species in the stressed interferon-β sample.
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In order to establish the specific nature of the stress-induced nonenzymatic PTM
of interferon-β, an online IXC/ESI MS/MS experiment was carried out by selecting
precursor ions within a 2480–2490 m/z window followed by ETD in the trap cell and
collisional activation of the products in the transfer cell (see the Experimental Section
for more detail). The ETD process was supplemented with collisional activation in order
to facilitate physical separation of protein ion fragments in the gas phase: since the
protein ions were generated under near-native conditions, they were expected to retain
some higher order structure in the gas phase. This phenomenon is known to prevent
fragment dissociation (following cleavage of a chemical bond connecting them) in many
cases due to the presence of residual noncovalent bonds (e.g., hydrogen bonds) holding
the two fragments together.127 Collisional heating eliminates these residual bonds and
facilitates the dissociation process.127 The fragmentation patterns obtained for both
species of interferon-β (see the Supporting Information) are nearly identical to each
other and feature abundant fragments within the Met1–Tyr30 and Ala142–Asn156
segments of the protein. The near absence of fragments due to backbone cleavages in
the protein segment flanked by Cys31 and Cys141 suggests that the disulfide bond
connecting them is intact in both forms of the protein and rules out both disulfide
scrambling and complete reduction as stress outcomes.
There is only one additional ion that is present in the fragmentation spectrum
averaged across the earlier-eluting peak of the BiNA2 species of interferon-β, namely,
b252+; the only other difference between the two sets of fragment ions is the 1 Da mass
shift for the c302+ ion recorded at earlier elution time (see insets in Figure 4.5). The
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protein segment covered by the latter fragment incorporates an asparagine residue
(Asn25), and deamidation at that position would indeed result in a mass increase of 1 Da,
which is reflected in the mass shift of c302+. Furthermore, deamidation at this position
would create a proximal acid–basic residue pair (Asp25Gly26Arg27), a motif known to
facilitate a direct bond cleavage of the amide bond adjacent to the aspartic acid
residue,128 hence the appearance of the b252+ fragment in the spectrum averaged across
the earlier-eluting peak. We also note that the monoisotopic mass of the b252+ fragment
is 1 Da higher compared to the theoretical mass of this fragment calculated based on
the sequence of intact interferon-β (and, therefore, consistent with a single
deamidation event occurring within the N-terminal segment of the protein). Taken
together, these observations not only provide unequivocal evidence that the
nonenzymatic PTM triggered by stress is indeed deamidation, but also allow the
affected site to be localized within the protein sequence. While there is a variety of
mass spectrometry-based methods to detect protein deamidation and localize the
affected sites,129, 130 a top-down approach to this task offers multiple advantages, such
as elimination of additional sample preparation steps (enzymatic digestion and
separation of peptide fragments).130 In addition to decreasing the analysis time to less
than 1 h, it also eliminates artifacts that could occur during sample preparation required
for bottom-up analysis.129 However, until recently the top-down approach was applied
only to small carbohydrate-free proteins. Combining top-down fragmentation with IXC
and online native ESI MS expands the capability of this technique dramatically by
enabling its application to significantly larger and more complex (glyco)protein samples.
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4.4. Conclusions
Online LC/MS and LC/MS/MS analysis of proteins and related macromolecules
has long been a workhorse in many fields of bioanalysis, including the
biopharmaceutical sector. Although the majority of applications make use of reversedphase chromatography, other modes of separation are also actively evaluated. Of
particular interest are methods that do not trigger protein denaturation during the
separation step, as they enable analysis of not only covalent (primary) structure, but
also higher order structure (including conformation and quaternary assembly). IXC is
shown in this work to be a very attractive candidate for these analyses, as it can be
applied to a wide range of challenging targets of interest to biopharmaceutical and
biotechnology sectors, can be operated under conditions that do not disrupt protein
higher order structure, and can be interfaced with native ESI MS. The latter provides
information on both identity of components of protein-based products (by measuring
masses) and their conformational integrity (via analysis of ionic charge state
distributions), while the former allows isomers (as well as isoforms with nearly
indistinguishable masses) to be separated. Incorporation of the top-down fragmentation
step in the IXC/ESI MS workflow allows stress-induced nonenzymatic PTMs to be
detected and localized in very complex and heterogeneous samples on the background
of extensive enzymatic PTMs, such as glycosylation. Although the size of the largest
protein therapeutic interrogated using the new IXC/ESI MS method in this work is
relatively modest (23 kDa), a work is currently underway in our laboratory to expand the
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reach of this new methodology to significantly larger and more heterogeneous targets,
including PEGylated glycoproteins.
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FIGURES

Figure 4.1 IXC/ESI MS analysis of a mixture of SATA-conjugated Lz: a UV chromatogram, a total
ion chromatogram, and extracted ion chromatograms for unmodified Lz and conjugates with
different loadings (left panel) and ESI mass spectra (right panel) averaged across
chromatographic peaks as indicated with colored dots on the chromatogram. The inset shows
zoomed views of charge states +7 (note that the top spectrum contains ionic contributions from
both SATA2·Lz and SATA3·Lz). The total amount of injected protein was 0.1 mg. The arrow
indicates a point in time when the eluate was directed to the ESI source.
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Figure 4.2 IXC/ESI MS analysis of a mixture of intact (fully oxidized) Lz and a fully reduced and
alkylated Lz: a UV chromatogram (gray trace), a TIC chromatogram (black trace), and extracted
ion chromatograms for ions representing the fully reduced (red) and intact Lz (blue). The inset
shows mass spectra averaged across the two chromatographic peaks.
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Figure 4.3 IXC/ESI MS analysis of Lz following selective reduction of a single disulfide bond: a UV
chromatogram (gray trace), a TIC chromatogram (black trace), and extracted ion
chromatograms for ions representing the species with three disulfide bonds (red), oxidized
intact (blue), and oxidized singly alkylated Lz (purple). The inset shows mass spectra averaged
across the three chromatographic peaks.
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Figure 4.4 IXC/ESI MS analysis of stressed interferon-β sample: TIC chromatogram and extracted
ion chromatograms of seven different glycoforms identified in the mass spectrum of the protein
sample not subjected to separation (shown in inset). The carbohydrate chain structures were
assigned based on measured mass and are also shown in the inset (structure key: squares,
GlcNac residues; triangles, fucose residues; open circles, mannose residues; filled circles,
galactose residues; diamonds, sialic acid residues). The total amount of protein injected was 4
μg.
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Figure 4.5 Identification and localization of a stress-induced nonenzymatic PTM within the BiNA2
species of interferon-β by IXC/ESI MS/MS: TIC for all fragment ions produced by ETD and
collisional activation of precursor ions corresponding to the +9 charge state of the BiNA2 species
(black trace) and extracted ion chromatograms corresponding to two different isotopic peaks
within the c302+ fragment ion (blue, m/z 1826.9; red, m/z 1825.4). The insets on the left show
isotopic distributions of fragment ions that are observed in both chromatographic peaks (c302+
and y172+) and unique to the earlier-eluting species (b252+). The inset on the right shows overall
fragmentation patterns for the two chromatographic peaks.
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Supporting information

Figure S6. Top-down fragmentation patterns observed for interferon-β species eluting at
17.5 min (peak 1) and 19 min (peak 2) in the chromatogram shown in Figure 4.5.

Table S.1.Relative signal intensities of SATAnLz conjugates from UV chromatogram and XIC’s
using the heights of peaks resolved in the UV chromatogram
Elution time
of peaks
(min.)

Relative abundances, %
UV
chromatogram

Extracted ion
chromatogram (XIC)

52.0

100

100

50.1

99.7

88.2

48.1

28.6

29.4

46.9

23.1

23.5

45.1

15.3

17.6

42.1

73.0

63.5
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CHAPTER 5
CHARACTERIZATION OF PEGYLATED-PROTEIN CONJUGATES BY WEAK CATION
EXCHANGE CHROMATOGRAPHY WITH ONLINE DETECTION BY NATIVE ESI MS
SUPPLEMENTED WITH GAS PHASE REACTIONS
5.1. Overview
Covalent attachment of poly ethylene glycol (PEG) to proteins has demonstrated
to be the most successful approach to improve pharmacokinetic and pharmacodynamics
profile of protein drugs.131 PEGylation increases the efficacy of protein drugs by
improving solubility, stability over wide pH and temperature range, decreasing renal
clearance, and limiting toxicity and immunogenicity.132 All of these eventually contribute
to less frequent administration of PEGylated protein drug to achieve the same
therapeutic outcome as its non-PEGylated form. However, due to polydispersity of PEG
molecule, PEGylation of protein increases complexity of the sample making its analytical
characterization very challenging.
Structural heterogeneity of PEGylated proteins occurs due to the presence of
complex species differing in the number of PEG chains conjugated, sites of conjugation,
and lengths of PEG chains. Many analytical methods have been reported to analyze the
presence of positional isomers in PEGylated proteins, some of these involved enzymatic
treatment to leave behind chemical tags to identify site of conjugation,133 use of new
PEG derivatives,134 and using chromatographic separation followed by top-down MS
analysis.135 Strategies have also been reported for site specific conjugation of proteins
with PEG.9,

136

Apart from heterogeneity due to PEG chain, an additional level of
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complexity could arise in PEGylated proteins due to the presence of enzymatic post
translational modifications (e.g., glycosylation) or non-enzymatic post translational
modifications (e.g., oxidation, deamidation).
Electrospray ionization mass spectrometry (ESI MS) has demonstrated to be very
useful for structural characterization of biopharmaceutical products.32 While native ESI
MS has been particularly useful as a tool of providing information on mass,
conformational integrity and interactions of protein drugs, it often fails for highly
heterogeneous samples (e.g., PEGylated proteins for reasons mentioned in the
preceding paragraphs). To analyze such samples ESI MS supplemented with limited
charge reduction introduced by our lab has shown a lot of potential, and has indeed
been applied to analyze highly glycosylated proteins and their complexes, and soluble
protein aggregates.70, 137 In chapters 2 and 4 native ESI MS based methods have also
been presented in which chromatographic separation of various protein species by size
exclusion chromatography or ion exchange chromatography (IXC) helped in the analysis
of protein heterogeneity.
IXC is also helpful in the analysis of PEGylated proteins; a method was reported
from our lab by combining separation capabilities of IXC and top-down tandem MS to
monitor positional isomers and map PEGylation sites on a 8.6 kDa ubiquitin protein
conjugated with 5kDa PEG chain.135 It also presented important fundamental aspects to
reduce the complexity of mass spectrum (related to polydispersity of PEG) using
collisional activated dissociation (CAD). In this work a new analytical strategy by
combining ion exchange chromatography with online native ESI MS detection is
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presented to analyze proteins conjugated with larger PEG chain. Limited charge
reduction (LCR) or CAD is implemented in online LC/MS mode for characterization of
PEGylation stoichiometry and different post translational modifications. This strategy
have been applied to a complex mixture containing 22 kDa glycoprotein conjugated with
a 20kDa PEG chain.
5.2. Materials and Methods
Stressed (partially deamidated) sample of PEGylated glycoprotein was provided
by Biogen (Cambridge, MA). All other chemicals used in this work were of analytical
grade or higher. Online IXC/MS analysis of stressed PEGylated glycoprotein was carried
out directly by diluting the sample in 100 mM ammonium acetate, pH 5.5 to a required
concentration.
Ion-exchange chromatography was performed on an Agilent 1100 HPLC (Agilent
Technologies, Santa Clara, CA) equipped with a 2 mm × 250 mm weak cation-exchange
column ProPac WCX-10 (Thermo Scientific Waltham, MA). Ammonium acetate at pH 5.5
was used for MS-compatible gradient elution (100 mM in mobile phase A and 1 M
mobile phase B). The total flow rate was maintained at 0.2 mL/minute. Linear gradient
reaching 25% B over 50 minutes after equilibration with mobile phase A for 3 minutes
was used. Concentration of PEGylated glycoprotein used was 1mg/ml and was injected
using a 20 µl sample loop. Upon exiting the column, the eluate was directed to online
detection by native ESI MS without any solvent modification or flow splitting using
Synapt G2Si (Waters, Milford, MA) hybrid quadrupole/time-of-flight mass spectrometer.
LCR was carried using electron transfer dissociation (ETD) on narrow population of ions
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isolated at m/z 1150 with 10 m/z isolation window. The conditions were optimized as
follows: capillary voltage, 2.5 kV, sampling cone, 5.0 V; source offset, 80 V; desolvation
temperature, 400 °C; source temperature, 120 °C, cone gas flow, 45 L/h; desolvation gas
flow, 600 L/h; make up gas flow, 35L/h; trap gas, 33.0 ml/min; transfer gas, 0.8 ml/min;
trap wave height, 0.08 V. CAD was carried out on ions isolated at m/z 1050 using 10 m/z
window in transfer cell by setting the collision energy at 25.0V and transfer gas to 2.0
ml/min.
5.3. Results and Discussion
Separation of this stressed PEGylated glycoprotein by WCX yielded four partially
resolved peaks along with an inflection point at 27-28 minutes interval (figure 5.1). The
species resolved by WCX could represent positional isomers and species with different
number of PEG chains conjugated to protein. In the case of this protein the presence of
positional isomers can be ruled out as PEGylation chemistry was optimized to conjugate
specifically at N terminal. However extensive heterogeneity due to the presence of
various glycoforms and deamidated forms could also lead to occurrence of different
PEGylated species. All these factors contributing to heterogeneity along with multiple
ESI MS charge states resulted in completely unresolved mass spectra detected for all of
the WCX peaks as shown in the upper right panel of figure 5.1. These mass spectra imply
occurrence of ion at each m/z in 800 – 1400 m/z range.
To analyze this sample LCR using ETD in the online WCX/ESI MS mode was
implemented. For the entire duration of LC, LCR was carried out on a narrow population
of ions isolated at m/z 1150. Charge state ladder resulting from this experiment enabled
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detection of the mass of isolated ions. In the bottom right panel of figure 5.1, a mass
spectrum obtained by averaging ESI MS LCR scans for ions (m/z 1150) eluting at 30 – 32
minutes is shown. Deconvolution of this mass spectrum gave a mass of ~45 kDa, which
is in agreement with 1:1 PEGylation of glycoprotein taking into account molecular
weight distribution of 20kDa PEG chain and molecular weight of this glycoprotein
(22kDa). ESI MS LCR data of m/z 1150 ions detected from other WCX peaks also gave
identical charge ladder deconvoluting to a mass consistent with 1:1 PEGylation
stoichiometry. This way by using LCR in conjunction with WCX/ESI MS, detection of
PEGylation stoichiometry was made possible, and all the stressed PEGylated
glycoprotein species resolved partially by WCX (figure 5.1) were found to be conjugated
with one chain of PEG. Unfortunately due to continuum of mass and broad LCR peaks
we were not able to differentiate various glycoforms.
For further analysis of this sample, a WCX/online ESI MS method was developed
in which CAD was applied to a narrow population of ions at m/z 1050 (isolated over
entire LC timescale). As seen in figure 5.2 the complexity of mass spectrum is decreased
significantly leading to detection of clusters of distinguishable ionic peaks. Charge state
assignment for each of these ionic clusters was carried out easily by dividing the
adjacent peak spacing with the repeating mass of PEG unit (44 u). The mass of these
ions correspond to cleavage of PEG chains following the route that produces B and C
ions as proposed by Lattimer and his colleagues.138 Similar ions were also produced,
when insource CAD was applied to PEGylated Ubiquitin as reported in the work carried
out previously in our lab.135 CAD conditions were optimized to cleave most of the PEG
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chain keeping the polypeptide backbone of the glycoprotein intact (figure 5.2). Multiply
charged ion clusters corresponding to six PEG molecules bound to intact glycoprotein
(B6+14 - B6+10 ions) were detected. These features led to simplified mass spectra enabling
identification of different stressed PEGylated glycoforms present in the sample as they
are separated by WCX (see right panel of figure 5.2).
Careful analysis of this data revealed the presence of PEGylated species bearing
BiNA2, TriNA3, BiNA1, and TriLACNA3 carbohydrates (see figures 5.3 and 5.4). Mass
spectrum correlating with PEG BiNA2 glycoforms was recorded in two chromatographic
peaks eluting at 28.2 – 29.3 and 31.9 – 33.5 minutes interval. Similarly based on ESI MS
mass measurements TriNA3 was found to elute at 25.0 – 28.0 and 30.0 – 31.4 minutes
interval. Identification of these glycoforms based on mass was further confirmed by
detection of fragment ions produced from cleavage of terminal carbohydrate chain
residues (sialic acid). As shown in figure 5.3, in addition to intact BiNA2 ion mass spectra
detected at 28.2 – 29.3 and 31.9 – 33.5 minutes also showed ions whose mass was
consistent with loss of one and two sialic acids. BiNA1 was confirmed to elute in the last
chromatographic peak based on mass and detection of fragment ions from loss of only
one sialic acid residue. Similarly TriNA3 glycoform (figure 5.4) showed ions from
fragmentation of up to 3 sialic acids. Though BiNA1 ion seen in figure 5.4 could be due
to fragmentation of GlcNAc and galactose units from TriNA2 form, it most likely appears
in this mass spectrum due to tailing of chromatographic peak (see extracted ion
chromatogram, XIC in figure 5.5).
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XIC plotted in a straightforward way using the corresponding ions led to an
artificial increase in XIC peak signal due to absence of baseline resolved mass spectra
(see mass spectra in figure 5.2). To eliminate this noise, XICs were produced by
subtracting ionic intensities of the two most abundant peaks belonging to the same
cluster of glycoform ions (e.g., XIC of BiNA2 glycoform using the BiNA1 fragment ions
was made by subtracting XIC’s abundance of 2033.0 and 2037.6 m/z ions). It is not
surprising to see the presence of two chromatographic peaks for each glycoform (BiNA2
and TriNA3) of this stressed PEGylated glycoprotein; a similar observation was made in
chapter 3 when interferon was analyzed by WCX/ESI MS. Therefore the earlier eluting
chromatographic peaks of each glycoform most likely represent PEGylated deamidated
fraction of TriNA3 and BiNA2.
5.4. Conclusions
Growing trend of heterogeneity in biopharmaceuticals occurring either naturally
or induced by chemical modification (PEGylation in this work) presents a serious
challenge to analytical characterization. In this chapter analytical strategy has been
presented, which combined chromatographic separation along with various gas phase
chemistry techniques (ETD, CAD) in ESI MS. WCX separation has proved to be very
powerful in delineating the presence of non-enzymatic PTM (deamidation) on intact
protein glycoforms, which is not possible using bottom-up MS approach or standard
RPLC/MS. The feasibility of carrying out these kinds of gas phase measurements in
online mode helps by decreasing the analysis time, and also illustrates a novel method
to analyze such highly heterogeneous samples. Interfacing WCX/ESI MS with LCR has
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been demonstrated to be suitable for characterization of stoichiometry of PEGylated
sample. This WCX/MS LCR workflow can also be used for characterization of noncovalent protein complexes involving such PEGylated proteins. For a thorough
characterization of PEGylated proteins implementing CAD just enough to cleave most of
the PEG chain has shown to be a promising approach to reduce complexity of mass
spectrum to identify various PTMs.
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FIGURES

Figure 5.1 IXC/ESI MS analysis of stressed PEGylated glycoprotein: total ion chromatogram (TIC)
shown in black trace (lower left panel) and the upper right panel shows mass spectra averaged
across the correspnding chromatographic peaks marked with same colored circles. Lower right
panel is from IXC ESI MS LCR analysis; charge state ladder detected for the isolated ions (m/z
1150) of chromatographic peak marked with green circle. LCR charge state ladders for the ions
detected in other chromatographic peaks were similar giving a mass of 45kDa.
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Figure 5.2 IXC/ESI MS CAD analysis of stressed PEGylated glycoprotein: a total ion
chromatogram (TIC) obtained from CAD of ions isolated at m/z 1050 is shown in black trace
(lower left panel) and the right panel shows mass spectra averaged across each
chromatographic peak. BiNA2 glycoform eluted at 28.2 - 29.3 and 31.9 - 33.5 minutes; TriNA2
and TriLACNA2 glycoforms at 25.0 - 28.0 and 30 .0 – 31.4 minutes; BiNA1 glycoform at 36.0 37.0 minutes interval.
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Figure 5.3 Zoom of +11 charge state of the mass spectra detected from IXC/ESI MS CAD of
stressed PEGylated glycoprotein. The carbohydrate ions were assigned based on measured
mass after subtraction of 6 PEG units’ mass. (structure key: squares, GlcNac residues; triangles,
fucose residues; open circles, mannose residues; filled circles, galactose residues; diamonds,
sialic acid residues). BiNA2 glycoform was detected in peaks eluting at 28.2 – 29.3 and 31.9 –
33.5 minutes range. BiNA1 eluted at 36.0 – 37.0 minutes interval.
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Figure 5.4 Zoom of +11 charge state of the mass spectra detected from IXC/ESI MS CAD of
stressed PEGylated glycoprotein. These mass spectra correspond to ions detected in TriNA3
glycoform. Ions marked with asterisk correspond to TriLACNA3. BiNA1 and BiNA0 glycoform
fragment ions are observed due to tailing of BiNA2 glycoform. The carbohydrate ions were
assigned based on measured mass after subtraction of 6 PEG units’ mass. (structure key: squares,
GlcNac residues; triangles, fucose residues; open circles, mannose residues; filled circles,
galactose residues; diamonds, sialic acid residues).
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Figure 5.5 Extracted ion chromatograms (XICs) of BiNA2 and TriNA3 PEGylated glycoforms
detected from WCX/ESI MS CAD analysis. XIC of BiNA2 glycoform was made using BiNA1
fragment ions detected from fragmentation of sialic acid residue from intact BiNA2 form.
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CHAPTER 6
CONCLUSIONS AND FUTURE OUTLOOK
Novel analytical methods combining non-denaturing liquid chromatography
separation with native ESI MS detection were developed in this work. These methods
have applications in characterization of biopolymer structure and interaction to help in
the development and quality control of biotherapeutics.
SEC with online native ESI MS detection method developed in chapter 2 allowed
characterization of higher order structure of proteins. It was shown to be useful in
probing conformational integrity and detection of soluble protein aggregates of a model
protein (bovine serum albumin), and characterize rapidly interconverting oligomeric
states of a recombinant glycoprotein human arylsulfatase A.
Using the same SEC/ESI MS workflow a method to measure kinetics and binding
affinity of transient protein interactions have also been developed. This method
involved fitting of experimental XICs with the profile generated using mathematical
solutions. Validation of this new method for analysis of protein interactions with 1:1 and
2:1 binding stoichiometry was carried out using the known binding of C-lobe of human
transferrin and transferrin variants, respectively with human transferrin receptor.
Further validation of this method will be carried out by changing the concentration of
interacting proteins, which will change binding kinetics, but should give the same
equilibrium dissociation constant. This method has significant potential as it does not
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require immobilization or labelling of proteins, works with small amount of sample, and
could be applied for complexes interacting with higher stoichiometries.

Combination of IXC with online native ESI MS detection was developed and
shown to be effective in characterization of conformational integrity and positional
isomers of protein conjugates (using chemically modified lysozyme as a model) and
PTMs of a biotherapeutic recombinant human interferon beta 1a. Top-down
fragmentation in this workflow (IXC/MS/MS of whole proteins) allowed non-enzymatic
PTMs to be identified in situations when the mass measurement alone was not
sufficient for an unequivocal conclusion to be reached. To characterize highly
heterogeneous PEGylated glycoprotein IXC/online ESI MS methods supplemented with
gas phase reactions (limited charge reduction and collisional activation) were
developed. These methods allowed detection of PEGylation stoichiometry and
glycoform distribution of intact PEGylated protein. A prerequisite for methods
developed in chapter 2 – 4 is that separation needs to be carried out in MS friendly
volatile mobile phase.
Separation by SEC applies for systems containing globular proteins, however it is
most likely to fail for complexes containing non-globular biopolymers (e.g.,
protein/DNA, protein/glycosaminoglycans), where differences in hydrodynamic radii is
not significant to allow separation based on size. To characterize transient complexes
containing such species, other modes of non-denaturing chromatography will be
implemented. IXC with online ESI MS detection will be particularly useful in this
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situation. Fitting XICs detected in IXC/ESI MS with the ADR equations similar to those
developed in chapter 3, kinetics and binding affinity of the complexes can be measured.
Unlike size filtration in SEC, linear velocities in IXC will depend on the interaction of the
species with the charged resin. This method will be applied for characterization of
protein/DNA complexes, which plays an important role in gene regulation.
The feasibility of carrying out limited charge reduction in online LC/MS opens
exciting opportunities. Implementing this feature in the SEC/ESI MS method developed
in chapter 3 and in IXC/ESI MS will enable qualitative analysis of interaction of highly
heterogeneous biopolymers and to measure kinetics and binding affinity. Transient
complexes that will be characterized using these methods include highly glycosylated
proteins (e.g., hemoglobin-drug conjugate binding to haptoglobin), protein-polymer
conjugates, and linear polysaccharides.
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APPENDIX
APPENDIX TO CHAPTER 3

Derivation of partial derivative equation for rhASA (chapter 3)
Assuming a short lived intermediate tetramer (M4); M2 ⇌ M8 transition of rhASA can
be understood by the following rate equation80
𝑘 (𝑠𝑠𝑠𝑠)

𝑘 (𝑓𝑓𝑓𝑓)

2𝑀2 ⇌𝑘2−2 (𝑓𝑓𝑓𝑓) 𝑀4 ; 2𝑀4 ⇌𝑘4−4 (𝑠𝑠𝑠𝑠) 𝑀8

(1)

The cumulative rates of octamer production and loss under steady state condition will
be
1

2
𝑅𝑑𝑑𝑑𝑑𝑑𝑑 = 𝑘−4 𝐶𝑀8 ; 𝑅𝑎𝑎𝑎𝑎𝑐 = 2 𝑘2 𝐶𝑀2

(2)

Concentration of M8 at any point x across the column length (0 < x < L) will also be
affected by longitudinal transfer and diffusion.
Mass transfer will be characterized by hydrodynamic flux through column cross-section
S. Hydrodynamic flux (JM8) of M8 depends on the linear velocity (uM8) and concentration
gradient (CM8)
𝐽𝑀8 (𝑥, 𝑡) = 𝑢𝑀8 · 𝐶𝑀8 (x, t)

(3)

Diffusion is determined by diffusion coefficient (DM8) and concentration gradient for M8
𝐽𝑀8 (𝑥, 𝑡) = −𝐷𝑀8 ·

𝜕 𝐶𝑀8 (𝑥,𝑡)

(4)

𝜕𝜕

Total change of the number of M8 molecules within the infinitely small slice of the
column volume (S.δx) over an infinitely small period of time δt will reflect a difference
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between the rates of association and dissociation, as well as the difference between the
incoming flux of M8 and the outgoing flux
𝛿𝐶𝑀8 · 𝑆𝑆𝑆 = −𝑆 · 𝑢𝑀8 · 𝛿𝐶𝑀8 · 𝛿𝛿 + 𝑆 · 𝐷𝑀8 · 𝛿 �
· 𝑅𝑎𝑎𝑎𝑎𝑎 · 𝛿𝛿

𝜕𝐶𝑀8 (𝑥, 𝑡)
� · 𝛿𝛿 − 𝑆𝑆𝑆 · 𝑅𝑑𝑑𝑑𝑑𝑑𝑑 · 𝛿𝛿 + 𝑆𝑆𝑆
𝜕𝜕

(5)

Association and dissociation terms are defined by eq.2. Since x and t are independent
variables, eq. 5 can be re-written in the form of a partial differential equation, and a
similar equation can be constructed for the dimer concentration.
2

⎧ 𝜕𝐶𝑀8 = −𝑢 ∙ 𝜕𝐶𝑀8 + 𝐷 ∙ 𝜕 𝐶𝑀8 − 𝑘 𝐶 + 1 𝑘 𝐶2
𝑀8
𝑀8
−4 𝑀8
𝑀2
⎪ 𝜕𝜕
2
𝜕𝜕
𝜕𝜕2
2

𝜕𝐶𝑀2
𝜕2 𝐶𝑀2
⎨𝜕𝐶𝑀2
2
= −𝑢𝑀2 ∙
+ 𝐷𝑀2 ∙
⎪
2 + 4𝑘−4 𝐶𝑀8 − 2𝑘2 𝐶𝑀2
𝜕𝜕
𝜕𝜕
⎩ 𝜕𝜕

(6)

List of parameters used in the calculations of partial differential equations for FeTfC
and TfR interaction
uP = 1.465 cm/min
uR = 1.740 cm/min
uPR = 1.845 cm/min
DP = 0.0027cm2/min
DR = 0.0134 cm2/min
DPR = 0.0122cm2/min
List of parameters used in the calculations of partial differential equations for hTf and
TfR interaction
uP = 1.71 cm/min
uR = 1.74 cm/min

106

uPR = 1.87 cm/min
uP2R = 2.08 cm/min
DP = 0.0026 cm2/min
DR = 0.0134 cm2/min
DPR = 0.0110 cm2/min
DP2R = 0.0090 cm2/min
List of parameters used in the calculations of partial differential equations for Fe2 bTf
and TfR interaction
uP = 1.67 cm/min
uR = 1.74 cm/min
uPR = 1.80 cm/min
uP2R = 2.00 cm/min
DP = 0.0026 cm2/min
DR = 0.0134 cm2/min
DPR = 0.0110 cm2/min
DP2R = 0.0090 cm2/min
List of parameters used in the calculations of partial differential equations for bTf and
TfR interaction
uP = 1.70 cm/min
uR = 1.74 cm/min
uPR = 1.87 cm/min
uP2R = 2.08 cm/min
DP = 0.0026 cm2/min
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DR = 0.0134 cm2/min
DPR = 0.0110 cm2/min
DP2R = 0.0090 cm2/min
Initial (injection) concentrations of all the components were represented as boxcar
functions with a width σ = 0.21 cm
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